Bicyclic aza compounds as muscarinic M1 and / or M4 receptor agonists

Novel bicyclic aza compounds act as selective muscarinic M1 and/or M4 receptor agonists, improving treatment efficacy for Alzheimer's disease, schizophrenia, and pain management by minimizing side effects and enhancing subtype selectivity.

JP7583721B2Active Publication Date: 2024-11-14NXERA PHARMA UK LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2021532234
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-12-07
Filing Date
2019-12-09
Publication Date
2024-11-14
Estimated Expiration
2039-12-09

AI Technical Summary

Technical Problem

Existing muscarinic receptor agonists, such as xanomeline, cause significant side effects like nausea, gastrointestinal issues, and bradycardia, limiting their effectiveness in treating Alzheimer's disease and schizophrenia, while current treatments for pain, particularly neuropathic pain, lack selectivity for muscarinic receptor subtypes M1 and M4.

Method used

Development of novel bicyclic aza compounds that act as selective muscarinic M1 and/or M4 receptor agonists, exhibiting high selectivity for these subtypes and reduced activity on M2 and M3 receptors, thereby minimizing side effects and enhancing therapeutic efficacy.

Benefits of technology

The compounds provide effective treatment for Alzheimer's disease, schizophrenia, and various pain types with reduced side effects and improved selectivity, addressing the limitations of existing agonists.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583721000001
    Figure 0007583721000001
  • Figure 0007583721000002
    Figure 0007583721000002
  • Figure 0007583721000003
    Figure 0007583721000003
Patent Text Reader

Abstract

The present invention relates to compounds that are agonists of the muscarinic M1 and / or M4 receptors and are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and therapeutic uses of the compounds. The compounds provided have the formula (I): 1 ;X 2 ;R 1 and R 4 is as defined herein. JPEG2022511869000053.jpg1848
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a class of novel heterocyclic compounds, their salts, pharmaceutical compositions containing them, and their use in the treatment of the human body. In particular, the present invention is directed to a class of compounds that are agonists of the muscarinic M1 and / or M4 receptors and are therefore useful in the treatment of Alzheimer's disease, schizophrenia, cognitive disorders, and other diseases mediated by the muscarinic M1 / M4 receptors, as well as in the treatment or alleviation of pain. [Background technology]

[0002] Muscarinic acetylcholine receptors (mAChRs) are members of the G protein-coupled receptor superfamily that mediate the actions of the neurotransmitter acetylcholine in both the central and peripheral nervous systems. Five mAChR subtypes, namely M1-M5, have been cloned. M1mAChRs are expressed primarily postsynaptically in the cortex, hippocampus, striatum and thalamus. M2mAChRs are located primarily in the brainstem and thalamus, but also in the cortex, hippocampus and striatum, where they are present at cholinergic synaptic terminals (Langmead et al., 2008 Br J Pharmacol). However, M2mAChRs are also expressed peripherally, on the cardiac tissue surface (M2mAChRs mediate vagal innervation of the heart), and in smooth muscle and exocrine glands. M3mAChR is expressed at relatively low levels in the CNS, but is widely expressed in smooth muscle and glandular tissues such as sweat and salivary glands (Langmead et al., 2008 Br J Pharmacol).

[0003] Muscarinic receptors in the central nervous system, especially M1mAChR, play an important role in mediating higher cognitive processing. Diseases associated with cognitive impairment, such as Alzheimer's disease, are accompanied by loss of cholinergic neurons in the basal forebrain (Whitehouse et al., 1982, Science). In schizophrenia, which is also characterized by cognitive impairment, mAChR density is reduced in the prefrontal cortex, hippocampus and caudate putamen of schizophrenic subjects (Dean et al., 2002, Mol Psychiatry). Furthermore, animal models have shown that blockade or lesion of central cholinergic pathways results in severe cognitive deficits, and nonselective mAChR antagonists induce psychotomimetic effects in psychiatric patients. Coronergic replacement therapy has been based mainly on the use of acetylcholinesterase inhibitors, which block the destruction of endogenous acetylcholine. These compounds show efficacy against symptomatic cognitive decline in the outpatient clinic but cause dose-limiting side effects due to stimulation of peripheral M2 and M3 mAChRs, including impaired gastrointestinal motility, bradycardia, nausea and vomiting (http: / / www.drugs.com / pro / donepezil.html; http: / / www.drugs.com / pro / rivastigmine.html).

[0004] Further discovery efforts have been aimed at identifying direct M1 mAChR agonists that target cognitive enhancement. Such efforts have led to the identification of a range of agonists, exemplified by compounds such as xanomeline, AF267B, sabcomeline, miramelin, and cevimeline. Many of these compounds have shown high efficacy in preclinical models of cognition in both rodents and / or non-human primates. Mirameline has shown efficacy against scopolamine-induced deficits in working and spatial memory in rodents. Sabcomeline has shown efficacy in visual object recognition tasks in marmosets, and xanomeline has reversed mAChR antagonist-induced deficits in cognitive performance in a passive avoidance paradigm.

[0005] Alzheimer's disease (AD) is the most common neurological disorder affecting elderly people (26.6 million worldwide in 2006), resulting in severe memory loss and cognitive dysfunction. The etiology of the disease is complex, but is characterized by two prominent brain sequelae: the aggregation of amyloid plaques, mainly composed of amyloid-β-peptide (Aβ), and neurofibrillary tangles formed by hyperphosphorylated tau protein. The accumulation of Aβ is considered a central feature in the progression of AD, and therefore many putative therapies for the treatment of AD currently target the inhibition of Aβ production. Aβ results from the proteolytic cleavage of membrane-bound amyloid precursor protein (APP). APP is processed by two pathways: nonamyloidogenic and amyloidogenic. Cleavage of APP by γ-secretase is common to both pathways, but in the former, APP undergoes cleavage by α-secretase, resulting in soluble APPα. A cleavage site exists within the Aβ sequence, thereby preventing its formation. However, in the amyloidogenic pathway, APP undergoes cleavage by β-secretase, resulting in soluble APPβ and also Aβ. In vitro studies have shown that mAChR agonists can promote the processing of APP towards the soluble, nonamyloidogenic pathway. In vivo studies have shown that the mAChR agonist AF267B modifies disease-like pathology in 3xTgAD transgenic mice, a model of various components of Alzheimer's disease (Caccamo et al., 2006, Neurol). Finally, the mAChR agonist cevimeline has been shown to result in a small but significant reduction in cerebrospinal fluid levels of Aβ in Alzheimer's patients, thus demonstrating potential disease-modifying efficacy (Nitsch et al., 2000, Neurol).

[0006] Furthermore, preclinical studies suggest that mAChR agonists display an atypical antipsychotic-like profile in a range of preclinical paradigms. The mAChR agonist xanomeline reverses several dopamine-driven behaviors, including amphetamine-induced locomotion in rats, apomorphine-induced tree climbing in mice, dopamine agonist-driven rotational movement in unilateral 6-OH-DA-lesioned rats, and amphetamine-induced hyperlocomotion in monkeys (without EPS loading). It has also been shown to inhibit A10, but not A9, dopamine cell firing and conditioned avoidance in the prefrontal cortex and nucleus accumbens, but not in the striatum, and induce c-fos expression in rats. All of these data suggest an atypical antipsychotic-like profile (Mirza et al., 1999 CNS Drug Rev). Muscarinic receptors are also involved in the neurophysiology of addiction. The reinforcing effects of cocaine and other addictive substances are mediated by the mesolimbic dopamine system, where behavioral and neurochemical studies have demonstrated that cholinergic muscarinic receptor subtypes play a key role in regulating dopaminergic neurotransmission. For example, M(4)(- / -) mice have demonstrated significantly enhanced reward-driven behavior as a result of exposure to cocaine (Schmidt et al. Psychopharmacology (2011) August;216(3):367-78). Furthermore, xanomeline has been demonstrated to block the effects of cocaine in these models.

[0007] Muscarinic receptors are also involved in the control of movement and potentially represent targets for novel treatment of movement disorders such as Parkinson's disease, ADHD, Huntington's disease, Tourette's syndrome, and other syndromes associated with dopaminergic dysfunction as a potential pathogenic factor-driven disease.

[0008] Xanomeline, sabcomeline, miramelin and cevimeline are all in various stages of clinical development for treating Alzheimer's disease and / or schizophrenia. Phase II clinical studies with xanomeline have demonstrated efficacy against various cognitive symptom domains, including behavioral disorders and hallucinations associated with Alzheimer's disease (Bodick et al., 1997, Arch Neurol). This compound has also been evaluated in small Phase II studies of schizophrenic drugs, resulting in significant reductions in positive and negative symptoms compared to placebo controls (Shekhar et al., 2008, Am J Psych). However, in all clinical studies, xanomeline and other related mAChR agonists show unacceptable safety margins with respect to cholinergic side effects, including nausea, gastrointestinal pain, diarrhea, diaphoresis (excessive sweating), hypersalivation (excessive salivation), fainting and bradycardia.

[0009] Muscarinic receptors are involved in central and peripheral pain. Pain can be classified into three different types: acute, inflammatory and neuropathic. Acute pain serves an important defense function that keeps the organism safe from stimuli that may cause tissue damage, but postoperative pain management is necessary. Inflammatory pain can occur for a number of reasons, including tissue damage, autoimmune responses and pathogen invasion, and is triggered by the action of inflammatory mediators such as neuropeptides and prostaglandins, which lead to neuronal inflammation and pain. Neuropathic pain is associated with abnormal pain sensations to non-painful stimuli. Neuropathic pain is associated with several different diseases / injuries, such as spinal cord injury, multiple sclerosis, diabetes (diabetic neuropathy), viral infections (such as HIV or herpes). Neuropathic pain is also common to cancer, both as a result of disease or chemotherapy side effects. Activation of muscarinic receptors has been shown to have analgesic effects in several pain conditions, with receptor activation in the spinal cord and the highest pain centers in the brain. Increasing endogenous levels of acetylcholine with acetylcholinesterase inhibitors, and direct activation of muscarinic receptors with agonists or allosteric modulators have been shown to have analgesic activity. In contrast, blocking muscarinic receptors with antagonists or using knockout mice increases pain sensitivity. Evidence for the role of M1 receptors in pain is reviewed by D.F. Fiorino and M. Garcia-Guzman, 2012.

[0010] More recently, a few compounds have been identified that show improved selectivity for the M1 mAChR subtype compared to peripherally expressed mAChR subtypes (Bridges et al., 2008, Bioorg Med Chem Lett; Johnson et al., 2010, Bioorg Med Chem Lett; Budzik et al., 2010, ACS Med Chem Lett). Despite the increased level of selectivity resulting in reduced activity on the M3 mAChR subtype, some of these compounds maintain significant agonist activity on both this subtype and the M2 mAChR subtype. Herein, we describe a series of compounds that unexpectedly show high levels of selectivity for M1 and / or M4 mAChR compared to M2 and M3 receptor subtypes.

[0011] WO2014 / 122474 relates to muscarinic M4 receptor agonist compounds. Summary of the Invention [Means for solving the problem]

[0012] The present invention The present invention provides compounds having activity as muscarinic M1 and / or M4 receptor agonists. More particularly, the present invention provides compounds that exhibit selectivity for the M1 and / or M4 receptors over the M2 and M3 receptor subtypes. Thus, in a first embodiment (embodiment 1.1), the present invention provides compounds of formula (1):

[0013] [ka] or a salt thereof (wherein X 1 and X 2 is a saturated hydrocarbon group containing, taken together, a total of 5 to 9 carbon atoms and 0 or 1 oxygen atom, and is selected from the group consisting of the following moieties:

[0014] [ka] are saturated hydrocarbon groups linked together to form a mono- or bicyclic ring system, optionally substituted by one or more fluorine atoms; R 1 COR 5 ;COOR 5 ;CONR 5 R 6 ;C(=NR 5 )R 6 ;OCOR 5 ;NR 7 COR 5 ;NR 7 CONR 5 R 6 ;NR 7 COOR 5 ;OCONR 5 R 6 ;CH2OR 5 ;CH2NR 5 R 6 ;CH2COR 5 ;CH2COOR 5 ;CH2CONR 5 R 6 ;CH2C(=NR 5 )R 6 ;CH2OCOR 5 ;CH2NR 7 COR 5 ;CH2NR 7 CONR 5 R 6 ;CH2NR 7 COOR 5 ;CH2OCONR 5 R 6 ;CH2CH2NR 5 R 6 an optionally substituted 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms, or C 1~6non-aromatic hydrocarbon groups, optionally substituted with 1 to 6 fluorine atoms or with a 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms, in which 1 or 2, but not all, carbon atoms of the hydrocarbon group may be replaced by heteroatoms selected from O, N and S and their oxidized forms; R 4 is H or C optionally substituted with 1 to 6 fluorine atoms 1~6 a non-aromatic hydrocarbon group in which one or two, but not all, carbon atoms of the hydrocarbon group may be replaced by a heteroatom selected from O, N and S and their oxidized forms; R 5 , R 6 and R 7 are the same or different and each independently represent hydrogen, non-aromatic C 1~6 a hydrocarbon group, optionally substituted by one or more fluorine atoms or a 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms, or R 5 and R 6 can be joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms). to provide.

[0015] Particular and preferred compounds of formula (1) are as defined in embodiments 1.2 to 1.52 below: 1.2 R 1 But CH2CONR 5 R 6 ;OCONR 5 R 6 , or C 1~6The compound according to embodiment 1.1, selected from non-aromatic hydrocarbon groups (substituted with a 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms).

[0016] 1.3 R 1 But CH2CONR 5 R 6 or OCONR 5 R 6 The compound according to any one of embodiments 1.1 or 1.2, selected from:

[0017] 1.4 R 1 But CH2CONR 5 R 6 The compound according to any one of embodiments 1.1 to 1.3,

[0018] 1.5 R 1 But OCONR 5 R 6 The compound according to any one of embodiments 1.1 to 1.3,

[0019] 1.6 R 5 , R 6 and R 7 are the same or different, and each independently represents hydrogen, non-aromatic C 1~6 The compound according to embodiment 1.1, selected from a hydrocarbon group, optionally substituted with one or more fluorine atoms or with a 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms.

[0020] 1.7 R 5 The compound according to embodiment 1.6, wherein is C1-C3 alkyl.

[0021] 1.8 R 6 The compound according to embodiment 1.6, wherein is C1-C3 alkyl.

[0022] 1.9 R 7The compound according to embodiment 1.6, wherein is C1-C3 alkyl.

[0023] 1.10 R 5 , R 6 and R 7 The compound according to embodiment 1.6, wherein any of is selected from methyl, ethyl, and isopropyl.

[0024] 1.11 R 5 , R 6 and R 7 The compound according to embodiment 1.6, wherein any of is methyl.

[0025] 1.12 R 5 , R 6 and R 7 The compound according to embodiment 1.6, wherein any of is ethyl.

[0026] 1.13 R 5 , R 6 and R 7 The compound according to embodiment 1.6, wherein any of is isopropyl.

[0027] 1.14 R 1 But CH2CONR 5 R 6 or OCONR 5 R 6 (R 5 and R 6 is selected from methyl, ethyl and isopropyl.

[0028] 1.15 R 5 and R 6 are joined to each other to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms.

[0029] 1.16 R 1 But CH2CONR 5 R6 ;OCONR 5 R 6 or CH2CH2NR 5 R 6 (R 5 and R 6 are joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof.

[0030] 1.17 R 1 But CH2CONR 5 R 6 (R 5 and R 6 are joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof.

[0031] 1.18 R 1 But OCONR 5 R 6 (R 5 and R 6 are joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof.

[0032] 1.19 R 5 and R 6 The compound according to any one of embodiments 1.15-1.18, wherein:

[0033] 1.20 R 1 But the following:

[0034] [ka] The compound according to embodiment 1.1, selected from:

[0035] 1.21 R 5 and R 6 are bonded to each other, and R 1 But the following:

[0036] [ka] The compound according to any one of embodiments 1.15 to 1.18, selected from:

[0037] 1.22 R 5 and R 6 The compound according to any one of embodiments 1.15 to 1.18, wherein are linked together to form an azepane, pyrrolidine, piperidine, 1,4-oxazepane, 1-azaspiro[3.3]heptane, or morpholine ring system.

[0038] 1.23 R 4 C optionally substituted by H or 1 to 6 fluorine atoms 1~6 A compound according to any one of embodiments 1.1 to 1.22, which is a non-aromatic hydrocarbon group, in which one or two, but not all, carbon atoms are optionally replaced by heteroatoms selected from O, N and S and their oxidized forms.

[0039] 1.24 R 4 A compound according to any one of embodiments 1.1 to 1.22, wherein is selected from H, methyl, ethyl, ethynyl, and 1-propynyl.

[0040] 1.25 R 4 A compound according to any one of embodiments 1.1 to 1.22, wherein is H.

[0041] 1.26 R 4 The compound according to any one of embodiments 1.1 to 1.22, wherein is methyl.

[0042] 1.27X 1 and X 2are linked to form an 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, 6-azaspiro[3.4]octane, 2-azaspiro[3.4]octane, 2-azaspiro[3.3]heptane, 3-oxa-9-azabicyclo[3.3.1]nonane or 2-azabicyclo[2.2.2]octane ring system.

[0043] 1.28 part:

[0044] [ka] The bicyclic ring system formed by

[0045] [ka] The compound according to any one of embodiments 1.1 to 1.26, selected from:

[0046] 1.29 and below: Ethyl-3-(3-(2-(diethylamino)-2-oxoethyl)azetidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate; Ethyl-3-(3-(2-(ethyl(isopropyl)amino)-2-oxoethyl)azetidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate; Ethyl-3-(3-(2-oxo-2-(1-azaspiro[3.3]heptan-1-yl)ethyl)azetidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate; Ethyl-3-(3-(2-oxo-2-(piperidin-1-yl)ethyl)azetidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate; Ethyl-5-(3-(2-(diethylamino)-2-oxoethyl)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl-5-(3-(2-(ethyl(isopropyl)amino)-2-oxoethyl)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl-5-(3-(2-oxo-2-(piperidin-1-yl)ethyl)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl-5-(3-(2-(1,4-oxazepan-4-yl)-2-oxoethyl)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl-5-(3-(2-oxo-2-(1-azaspiro[3.3]heptan-1-yl)ethyl)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl-3-(3-(2-(diethylamino)-2-oxoethyl)azetidin-1-yl)-9-azabicyclo[3.3.1]nonane-9-carboxylate; Ethyl-3-(3-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azetidin-1-yl)-9-azabicyclo[3.3.1]nonane-9-carboxylate; Ethyl-3-(3-(2-oxo-2-(piperidin-1-yl)ethyl)azetidin-1-yl)-9-azabicyclo[3.3.1]nonane-9-carboxylate; Ethyl 6-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-2-azaspiro[3.3]heptane-2-carboxylate; Ethyl 2-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate; 1-(6-(ethoxycarbonyl)-6-azaspiro[3.4]octan-2-yl)azetidin-3-yl 1,4-oxazepane-4-carboxylate; Ethyl 6-(3-((ethyl(methyl)carbamoyl)oxy)azetidin-1-yl)-2-azaspiro[3.4]octane-2-carboxylate; Ethyl 6-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-2-azaspiro[3.4]octane-2-carboxylate; Methyl 6-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-2-azaspiro[3.4]octane-2-carboxylate; Ethyl 6-(3-((pyrrolidine-1-carbonyl)oxy)azetidin-1-yl)-2-azaspiro[3.4]octane-2-carboxylate; 1-(2-(ethoxycarbonyl)-2-azaspiro[3.4]octan-6-yl)azetidin-3-ylmorpholine-4-carboxylate; 1-(2-(ethoxycarbonyl)-2-azaspiro[3.4]octan-6-yl)azetidin-3-yl 1,4-oxazepane-4-carboxylate; Ethyl 3-(3-((azepane-1-carbonyl)oxy)azetidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate; 1-(8-(ethoxycarbonyl)-8-azabicyclo[3.2.1]octan-3-yl)azetidin-3-yl 1,4-oxazepane-4-carboxylate; Ethyl 5-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl 5-(3-((pyrrolidine-1-carbonyl)oxy)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl 5-(3-((piperidine-1-carbonyl)oxy)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl 5-(3-((azepane-1-carbonyl)oxy)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; 1-(2-(ethoxycarbonyl)-2-azabicyclo[2.2.2]octan-5-yl)azetidin-3-yl 1,4-oxazepane-4-carboxylate; Ethyl 3-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-9-azabicyclo[3.3.1]nonane-9-carboxylate; Ethyl 7-(3-((azepane-1-carbonyl)oxy)azetidin-1-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate; A compound according to any one of embodiments 1.1 to 1.28, selected from:

[0047] 1.30 A compound according to embodiment 1.1 as defined in any one of Examples 1 to 31.

[0048] 1.31 The compound according to any one of embodiments 1.1 to 1.30, having a molecular weight of less than 550, such as less than 500, or less than 450.

[0049] 1.32 A compound according to any one of embodiments 1.1 to 1.31 in the form of a salt.

[0050] 1.33 The compound according to embodiment 1.32, wherein the salt is an acid addition salt.

[0051] 1.34 The compound according to embodiment 1.32 or embodiment 1.33, wherein the salt is a pharma- ceutically acceptable salt. definition For the purposes of this application, the following definitions apply unless otherwise stated.

[0052] The term "treatment" in relation to the use of the compounds of formula (1) is used to describe any form of intervention in which the compound is administered to a subject suffering from, at risk of, or potentially at risk of suffering from the disease or disorder in question.Thus, the term "treatment" encompasses both prophylactic (preventative) treatment and treatment in which a measurable or detectable symptom of the disease or disorder is indicated.

[0053] The term "therapeutically effective amount" as used herein (e.g., in the method of treating disease or condition) refers to the amount of compound that is effective to produce the desired therapeutic effect.For example, when the condition is pain, the therapeutically effective amount is an amount that is sufficient to achieve the desired level of pain relief.The desired level of pain relief can be, for example, the complete disappearance of pain, or the reduction of the severity of pain.

[0054] The terms "alkyl," "heterocyclic," and "ether" are used in their conventional sense (eg, as defined in the IUPAC Gold Book) unless otherwise indicated.

[0055] The term "monocyclic" as used herein refers to an arrangement of atoms arranged to form a single ring structure. The term "bicyclic" as used herein refers to an arrangement of atoms arranged to form two linked rings. Bicyclic compounds can be carbocyclic or heterocyclic. Furthermore, the two rings can both be aliphatic, or both can be aromatic, or a combination of aliphatic and aromatic.

[0056] X above 1 , X 2 , R 1 and R 4 In the definition of, if specified, one or two, but not all, carbon atoms of the non-aromatic hydrocarbon group may be replaced by a heteroatom selected from O and N. When a carbon atom is replaced by a heteroatom, it is understood that the lower valence of the heteroatom compared to carbon means that fewer atoms are bonded to the heteroatom than are bonded to the replaced carbon atom. Thus, for example, the replacement of a carbon atom (valence 4) in a CH2 group with oxygen (valence 2) means that the resulting molecule contains two fewer hydrogen atoms, and the replacement of a carbon atom (valence 4) in a CH2 group with nitrogen (valence 3) means that the resulting molecule contains one fewer hydrogen atom.

[0057] Examples of exchange of heteroatoms for carbon atoms include the exchange of a carbon atom in the -CH2-CH2-CH2- chain by oxygen or sulfur to form ethers -CH2-O-CH2- or thioethers -CH2-S-CH2-; the exchange of a carbon atom in the group CH2-C≡CH by nitrogen to form the nitrile (cyano) group CH2-C≡N; the exchange of a carbon atom in the group -CH2-CH2-CH2- by C=O to form a ketone -CH2-C(O)-CH2-; the exchange of a carbon atom in the group -CH2-CH2-CH2- by S=O or SO2 to form These include replacement of a carbon atom in a -CH-CH-CH- chain with C(O)NH to give an amide -CH-CH-C(O)-NH-, replacement of a carbon atom in a -CH-CH-CH- chain with nitrogen to give an amine -CH-NH-CH-, and replacement of a carbon atom in a -CH-CH-CH- chain with C(O)O to give an ester (or carboxylic acid) -CH-CH-C(O)-O-. In each such replacement, at least one carbon atom of the hydrocarbon group must remain. salt Many compounds of formula (1) may exist in the form of salts, for example acid addition salts or, in certain cases, salts of organic and inorganic bases such as carboxylates, sulfonates and phosphates. All such salts are within the scope of the present invention, and references to compounds of formula (1) include the salt forms of the compounds defined in embodiments 1.32 to 1.34.

[0058] The salts are usually acid addition salts.

[0059] The salts of the present invention can be synthesized from parent compounds containing a basic or acidic moiety by conventional chemical methods, such as those described in Pharmaceutical Salts: Properties, Selection, and Use, P.Heinrich Stahl (ed.), Camille G.Wermuth (ed.), ISBN:3-90639-026-8, Hardcover, page 388, August 2002. In general, such salts can be prepared by reacting the compounds in their free acid or free base form with an appropriate base or acid in water or an organic solvent, or in a mixture of the two. Generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used.

[0060] Acid addition salts (as defined in embodiment 1.33) may be formed with a wide variety of acids, both inorganic and organic. Examples of acid addition salts falling within the scope of embodiment 1.33 include acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid (e.g., L-ascorbic acid), L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, butanoic acid, (+) camphoric acid, camphor-sulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, glycerinic ... cinnamic acid, citric acid, cyclamic acid, dodecyl sulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, glucuronic acid (e.g. D-glucuronic acid), glutamic acid (e.g. L-glutamic acid), α-oxoglutaric acid, glycolic acid, hippuric acid, hydrohalic acids (e.g. hydrobromic acid), , hydrogen chloride, hydrogen iodide), isethionic acid, lactic acid (e.g., (+)-L-lactic acid, (±)-DL-lactic acid), lactobioic acid, maleic acid, malic acid, (-)-L-malic acid, malonic acid, (±)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, These include the mono- or di-salts formed with acids selected from the group consisting of carboxylic acid, pamoic acid, phosphoric acid, propionic acid, pyruvic acid, L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, undecylenic acid and valeric acid, as well as acylated amino acids and cation exchange resins.

[0061] When compounds of formula (1) contain an amine functionality, they can be reacted, for example, with alkylating agents by methods well known to those skilled in the art to form quaternary ammonium salts. Such quaternary ammonium compounds are within the scope of formula (1).

[0062] The compounds of the invention can exist as mono- or di-salts depending on the pKa of the acid from which the salt is formed.

[0063] The salt forms of the compounds of the present invention are usually pharma- ceutically acceptable salts, and examples of pharma- ceutically acceptable salts are discussed in Berge et al., 1977, "Pharmaceutically Acceptable Salts," J.Pharm.Sci., vol. 66, pp. 1-19. However, pharma- ceutical non-acceptable salts may also be prepared as intermediates, which can then be converted to pharma- ceutical acceptable salts. Such non-pharma- ceutical acceptable salt forms, which may be useful, for example, in the purification or separation of the compounds of the present invention, also form part of the present invention. stereoisomer Stereoisomers are isomeric molecules that have the same molecular formula and sequence of bonded atoms, but differ only in the three-dimensional orientation of their atoms in space. Stereoisomers can be, for example, geometric isomers or optical isomers. geometric isomer For geometric isomers, isomerism can be due to different orientation of atoms or groups about a double bond, such as cis and trans (Z and E) isomerism about a carbon-carbon double bond, or cis and trans isomerism about an amide bond, or syn and anti isomerism about a carbon-nitrogen double bond (e.g., in an oxime), or rotational isomerism about a bond with restricted rotation, or cis and trans isomerism about a ring, such as a cycloalkane ring.

[0064] Thus, in another embodiment (embodiment 1.35), the invention provides a geometric isomer of a compound according to any one of embodiments 1.1 to 1.34. optical isomer Unless the context otherwise requires, when a compound of a formula contains one or more chiral centers and can exist in the form of two or more optical isomers, reference to the compound includes all its optical isomers (e.g., enantiomers, epimers and diastereoisomers), either as individual optical isomers, or mixtures (e.g., racemic mixtures), or two or more optical isomers.

[0065] Thus, in another embodiment (embodiment 1.36), the invention provides a compound according to any one of embodiments 1.1 to 1.35, which contains a chiral center.

[0066] Optical isomers may be characterized and identified by their optical activity (i.e., + and - isomers, or d and l isomers), or they may be characterized with respect to their absolute stereochemistry using the "R and S" nomenclature developed by Cahn, Ingold and Prelog, Advanced Organic Chemistry, 4th ed., John Wiley & Sons, New York, 1992, pp. 109-114, by Jerry March; see also Cahn, Ingold & Prelog, Angew. Chem. Int. Ed. Engl., 1966, vol. 5, pp. 385-415. Optical isomers can be separated by a number of techniques, including chiral chromatography (chromatography on a chiral support), which are well known to those skilled in the art. The optical isomers can be separated by forming diastereomeric salts with chiral acids such as (+)-tartaric acid, (-)-pyroglutamic acid, (-)-di-toluoyl-L-tartaric acid, (+)-mandelic acid, (-)-malic acid, and (-)-camphor-sulfonic acid as an alternative to chiral chromatography, separating the diastereoisomers by preferential crystallization, and then dissociating the salts to give the individual enantiomers as the free bases.

[0067] When the compounds of the present invention exist as two or more optical isomers, one of the enantiomers in the pair may exhibit advantages over the other enantiomer, for example, in terms of biological activity. Thus, in certain circumstances, only one of the pair of enantiomers, or only one of the diastereoisomers, may be desirable for use as a therapeutic agent.

[0068] Thus, in another embodiment (embodiment 1.37), the invention provides a composition containing a compound according to embodiment 1.36 having one or more chiral centers, wherein at least 55% (e.g., at least 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%) of the compound of embodiment 1.35 is present as a single optical isomer (e.g., enantiomer or diastereomer).

[0069] In one typical embodiment (embodiment 1.38), 99% or more (eg, substantially all) of the total amount of the compound of embodiment 1.36 (compound for use) is present as a single optical isomer.

[0070] For example, in one embodiment (embodiment 1.39), the compound exists as a single enantiomer.

[0071] In another embodiment (embodiment 1.40), the compound exists as a single diastereoisomer.

[0072] The present invention also provides mixtures of optical isomers, which may be racemic or non-racemic. Thus, the present invention provides: 1.41 The compound according to embodiment 1.36, in the form of a racemic mixture of optical isomers.

[0073] 1.42 The compound according to embodiment 1.36, in the form of a non-racemic mixture of optical isomers. Isotopes The compounds of the invention as defined in any one of embodiments 1.1 to 1.42 may contain one or more isotopic substitutions, and a reference to a particular element includes within its scope all isotopes of that element. For example, a reference to hydrogen includes within its scope: 1 H, 2 H(D) and 3 Similarly, when referring to carbon and oxygen, the following are included within their scope: 12 C. 13 C and 14 C, and 16O and 18 Contains O.

[0074] Similarly, reference to a particular functional group also includes within its scope isotopic variations, unless the context indicates otherwise. For example, reference to an alkyl group, such as an ethyl group, also encompasses variations in which one or more hydrogen atoms in the group are in the form of a deuterium or tritium isotope, such as, for example, an ethyl group in which all five hydrogen atoms are in the deuterium isotope form (perdeuteroethyl).

[0075] The isotope may be radioactive or non-radioactive. In one embodiment of the present invention (embodiment 1.43), the compound of any one of embodiments 1.1-1.42 contains a non-radioactive isotope. Such compounds are preferred for therapeutic use. However, in another embodiment (embodiment 1.44), the compound of any one of embodiments 1.1-1.42 may contain one or more radioactive isotopes. Compounds containing such radioactive isotopes may be useful in diagnostic situations. solvate The compounds of formula (1) as defined in any one of the embodiments 1.1 to 1.44 may form solvates. Preferred solvates are those formed by the incorporation of molecules of a non-toxic pharma- ceutically acceptable solvent into the solid-state structure (e.g., crystalline structure) of the compounds of the invention (hereinafter referred to as solvating solvents). Examples of such solvents include water, alcohols (such as ethanol, isopropanol and butanol) and dimethylsulfoxide. Solvates can be prepared by recrystallizing the compounds of the invention with a solvent or mixture of solvents containing a solvating solvent. Whether a solvate is formed in any given example can be determined by subjecting crystals of the compound to analysis using well-known standard techniques such as thermogravimetric analysis (TGE), differential scanning calorimetry (DSC) and X-ray crystallography. The solvates can be stoichiometric or non-stoichiometric solvates. Particularly preferred solvates are hydrates, and examples of the hydrates include hemihydrates, monohydrates, and dihydrates.

[0076] Thus, in further embodiments 1.45 and 1.46, the present invention provides: 1.45 The compound according to any one of embodiments 1.1 to 1.44, in a solvate form.

[0077] 1.46 The compound according to embodiment 1.45, wherein the solvate is a hydrate.

[0078] For a more detailed discussion of solvates and methods used to make and characterize solvates, see Bryn et al., Solid-State Chemistry of Drugs, 2nd Edition, 1999, ISBN 0-967-06710-3, published by SSCI, Inc of West Lafayette, IN, USA.

[0079] Alternatively, rather than existing as a hydrate, the compounds of the invention may be anhydrous. Thus, in another embodiment (embodiment 1.47), the invention provides a compound as defined in any one of embodiments 1.1 to 1.45 in anhydrous form (e.g., anhydrous crystalline form). Crystalline and amorphous forms The compound of any one of embodiments 1.1-1.47 may exist in a crystalline or non-crystalline (e.g., amorphous) state. Whether a compound exists in a crystalline state can be readily determined by standard techniques such as X-ray powder diffraction (XRPD). Crystals and their crystalline structures can be characterized using several techniques, including single crystal X-ray crystallography, X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and infrared spectroscopy, such as Fourier transform infrared spectroscopy (FTIR). The behavior of crystals under various humidity conditions can be analyzed by gravimetric vapor sorption studies, and also by XRPD. The determination of the crystal structure of a compound can be carried out by X-ray crystallography, which can be carried out according to conventional methods such as those described herein and those described in Fundamentals of Crystallography, C. Giacovazzo, HL Monaco, D. Viterbo, F. Scordari, G. Gilli, G. Zanotti and M. Catti (International Union of Crystallography / Oxford University Press, 1992 ISBN 0-19-855578-4(p / b), 0-19-85579-2(h / b)). This technique involves the analysis and interpretation of X-ray diffraction of a single crystal. In amorphous solids, the three-dimensional structure that is usually present in crystalline forms does not exist, and in amorphous forms the positions of the molecules relative to each other are substantially random, see for example Hancock et al. J.Pharm.Sci. (1997), vol. 86, p. 1.

[0080] Thus, in a further embodiment, the present invention provides: 1.48 The compound according to any one of embodiments 1.1 to 1.47, in a crystalline form.

[0081] 1.49 and below: (a) 50% to 100% crystalline, more particularly at least 50% crystalline, or at least 60% crystalline, or at least 70% crystalline, or at least 80% crystalline, or at least 90% crystalline, or at least 95% crystalline, or at least 98% crystalline, or at least 99% crystalline, or at least 99.5% crystalline, or at least 99.9% crystalline, e.g., 100% crystalline; A compound according to any one of embodiments 1.1 to 1.47.

[0082] 1.50 A compound according to any one of embodiments 1.1 to 1.47, in amorphous form. Prodrug The compounds of formula (1) as defined in any one of the embodiments 1.1 to 1.44 may exist in the form of a prodrug. By "prodrug" is meant, for example, any compound that is converted in vivo into a biologically active compound of formula (1) as defined in any one of the embodiments 1.1 to 1.44.

[0083] For example, some prodrugs are esters of active compounds (e.g., physiologically acceptable, metabolically labile esters). During metabolism, the ester group (-C(=O)OR) is cleaved to produce the active drug. Such esters can be formed, for example, by esterifying any hydroxyl groups present in the parent compound, optionally with prior protection of any other reactive groups present in the parent compound, followed by deprotection, if necessary.

[0084] Similarly, some prodrugs are activated by enzymes to yield the active compound or a compound that, upon further chemical reaction, yields the active compound (such as, for example, ADEPT, GDEPT, LIDEPT, etc.) For example, the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.

[0085] Thus, in another embodiment (embodiment 1.51), the invention provides a prodrug of a compound defined in any one of embodiments 1.1 to 1.44, wherein the compound contains a functional group transformable under physiological conditions to form a hydroxyl group or an amino group. Complexes and inclusion compounds Similarly, complexes of the compounds of embodiments 1.1-1.51 (eg, inclusion complexes or compounds with compounds such as cyclodextrins, or complexes with metals) are encompassed by formula (1) in embodiments 1.1-1.51.

[0086] Thus, in another embodiment (embodiment 1.52), the invention provides a compound according to any one of embodiments 1.1 to 1.51 in the form of a complex or inclusion compound. Biological Activity and Therapeutic Uses The compounds of the present invention have activity as muscarinic M1 and / or M4 receptor agonists. The muscarinic activity of the compounds can be determined using the phospho-ERK1 / 2 assay described in Example A below.

[0087] A major advantage of the compounds of the invention is that they are highly selective for the M1 and / or M4 receptors compared to the M2 and M3 receptor subtypes. The compounds of the invention are neither agonists nor antagonists of the M2 and M3 receptor subtypes. For example, the compounds of the invention typically have a pEC50 of at least 6 (preferably at least 6.5) for the M1 receptor in the functional assay described in Example A. 50 value, and an E of greater than 80 (preferably greater than 95) max While these compounds have pEC values ​​of less than 5 when tested against M2 and M3 subtypes in the functional assay of Example A, 50 value, and E less than 20% max It can have a value.

[0088] Some compounds of the invention have activity at both the M1 and M4 receptors.

[0089] Thus, in embodiments 2.1 to 2.21, the present invention provides: 2.1 A compound according to any one of embodiments 1.1 to 1.52 for use in medicine.

[0090] 2.2 A compound according to any one of embodiments 1.1 to 1.52 for use as a muscarinic M1, M4 or M1 and M4 receptor agonist.

[0091] 2.3 A pEC50 of greater than 6.9 for the M1 receptor in the assay of Example A herein, or an assay substantially similar thereto. 50 and at least 80 E max The compound according to any one of embodiments 1.1 to 1.52, which is a muscarinic M1 receptor agonist, having the formula:

[0092] 2.4 pEC greater than 7.0 50 The compound according to embodiment 2.3, which is a muscarinic M1 receptor agonist having the formula:

[0093] 2.5 At least 90 E for M1 receptors max The compound according to embodiment 2.3 or embodiment 2.4, having the formula:

[0094] 2.6 A pEC50 in the range of 6.0 to 8.7 for the M4 receptor in the assay of Example A herein, or a substantially similar assay. 50 and at least 60 E max The compound according to any one of embodiments 1.1 to 1.52, which is a muscarinic M1 and / or M4 receptor agonist, having the formula:

[0095] 2.7 A pEC50 in the range of 6.0 to 8.1 for the M4 receptor in the assay of Example A herein, or a substantially similar assay. 50 and at least 90 E maxThe compound according to any one of embodiments 1.1 to 1.52, which is a muscarinic M1 and / or M4 receptor agonist, having the formula:

[0096] 2.8 pEC in the range of 7.5-8.7 50 The compound according to embodiment 2.6, which is a muscarinic M4 receptor agonist having the formula:

[0097] 2.9 pEC in the range of 6.5-7.5 50 The compound according to embodiment 2.7, which is a muscarinic M4 receptor agonist having the formula:

[0098] 2.10 E of at least 75 for M4 receptors max The compound according to embodiment 2.6 or embodiment 2.8, having the formula:

[0099] 2.11 Efficacy of at least 95% against the M4 receptor max The compound according to embodiment 2.7 or embodiment 2.9, having the formula:

[0100] 2.12 A compound according to any one of embodiments 2.3 to 2.11 which is selective for the M1 and M4 receptors compared to the muscarinic M2 and M3 receptors.

[0101] 2.13 A compound according to embodiment 2.12 which is selective for the M1 receptor compared to the muscarinic M2 and M3 receptors.

[0102] 2.14 A compound according to embodiment 2.12 which is selective for the M4 receptor compared to the muscarinic M2 and M3 receptors.

[0103] 2.15 A compound according to any one of embodiments 2.3 to 2.5 which is selective for the M1 receptor compared to the muscarinic M2, M3 and M4 receptors.

[0104] 2.16 A compound according to any one of embodiments 2.3-2.5 which is selective for the M4 receptor compared to the muscarinic M1, M2 and M3 receptors.

[0105] 2.17 pEC50 < 5 for muscarinic M2 and M3 receptor subtypes 50 , and E below 50 max The compound according to any one of embodiments 2.3 to 2.16, having the formula:

[0106] 2.18 pEC50 of less than 4.5 for muscarinic M2 and M3 receptor subtypes 50 , and / or E less than 30 max The compound according to embodiment 2.17, having the formula:

[0107] 2.19 A compound according to any one of embodiments 1.1-1.52 and embodiments 2.3-2.16 for use in the treatment of a disease or condition mediated by the muscarinic M1 receptor.

[0108] 2.20 A compound according to any one of embodiments 1.1-1.52 and embodiments 2.3-2.16 for use in the treatment of a disease or condition mediated by the muscarinic M4 receptor.

[0109] 2.21 A compound according to any one of embodiments 1.1-1.52 and embodiments 2.3-2.16 for use in the treatment of a disease or condition mediated by muscarinic M1 and M4 receptors.

[0110] Due to their muscarinic M1, M4 or M1 and M4 receptor agonist activity, the compounds of the present invention can be used to treat Alzheimer's disease, schizophrenia and other psychotic disorders, cognitive disorders, and other diseases mediated by the muscarinic M1 or M1 and M4 receptors, and can also be used to treat various types of pain.

[0111] Thus, in embodiments 2.22 to 2.43, the present invention provides: 2.22 A compound according to any one of embodiments 1.1 to 1.52 for use in the treatment of a cognitive or psychotic disorder.

[0112] 2.23 The cognitive or psychotic disorder is: cognitive impairment, mild cognitive impairment (including mild cognitive impairment due to Alzheimer's disease and / or prodromal Alzheimer's disease), frontotemporal dementia, vascular dementia, dementia with Lewy bodies, presenile dementia, senile dementia, Friederich's ataxia, Down syndrome, Huntington's chorea, hyperkinesia, mania, Tourette's syndrome, Alzheimer's disease (fda.gov / downloads / Drugs / GuidanceComplianceRegulatoryInformation / Guidances / UCM596728).Impairment of cognitive function including prodromal Alzheimer's disease, and early Alzheimer's disease, stages 1, 2, and 3, as defined by the U.S. Food and Drug Administration's "Early Alzheimer's disease: Developing Drugs for Treatment," available at www.foodanddrugadministration.com / reports / alzheimer's-diseases-20150211.pdf; progressive supranuclear palsy; impairment of cognitive function including attention, adaptation, learning disorders, memory (i.e., memory disorder, amnesia, amnesic disorder, transient global amnesia syndrome, and age-associated memory impairment) and language functions; impairment as a result of stroke, Huntington's disease, Pick's disease dementia associated with other degenerative disorders such as cerebellar atrophy and amyotrophic lateral sclerosis; delirium or depression (pseudocognitive states), trauma, head trauma, age-related cognitive decline, stroke, neurodegeneration, drug-induced states, neurotoxic substances, age-related cognitive impairment, autism-related cognitive impairment, Down's syndrome, psychosis associated cognitive deficits and other acute or subacute conditions which may cause cognitive decline, such as cognitive disorders associated with electroconvulsive therapy; cognitive disorders due to drug abuse or withdrawal, including nicotine, cannabis, amphetamines, cocaine, attention deficit hyperactivity disorder (ADHD), and movement disorders such as Parkinson's disease, neuroleptic-induced parkinsonism, and tardive dyskinesia, schizophrenia, schizophreniform disorders, psychiatric depression, mania, acute mania, delusions , hallucinations and delusions, personality disorders, obsessive-compulsive disorders, schizophrenia, delusions, psychosis due to malignancy, metabolic disorders, endocrine disorders or narcolepsy, psychosis due to drug abuse or withdrawal, bipolar disorder and schizoaffective disorder, in embodiment 2.Compound for use by 22.

[0113] 2.24 A compound according to any one of embodiments 1.1 to 1.52 for use in the treatment of Alzheimer's disease.

[0114] 2.25 A compound according to any one of embodiments 1.1 to 1.52 for use in the treatment of schizophrenia.

[0115] 2.26 A method of treating a cognitive disorder in a subject (e.g., a mammalian patient, such as a human, e.g., a human in need of treatment for a cognitive disorder), comprising administration of a therapeutically effective dose of a compound according to any one of embodiments 1.1-1.52.

[0116] 2.27 The method according to embodiment 2.26, wherein the actual cognitive impairment comprises, is caused by, or is associated with a condition defined in embodiment 2.19.

[0117] 2.28 The method according to embodiment 2.27, wherein the cognitive impairment is caused by or associated with Alzheimer's disease.

[0118] 2.29 The method according to embodiment 2.27, wherein the cognitive disorder is schizophrenia.

[0119] 2.30 Use of a compound according to any one of embodiments 1.1 to 1.52 for the manufacture of a medicament for treating a cognitive disorder.

[0120] 2.31 The use according to embodiment 2.30, wherein the cognitive disorder comprises, is caused by, or is associated with a condition as defined in embodiment 2.23.

[0121] 2.32 The use according to embodiment 2.31, wherein the cognitive impairment is caused by or associated with Alzheimer's disease.

[0122] 2.33 The use according to embodiment 2.32, wherein the cognitive disorder is schizophrenia.

[0123] 2.34 A compound according to any one of embodiments 1.1-1.52 for treating or reducing the severity of acute, chronic, neuropathic or inflammatory pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpetic neuralgia, general neuralgia, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, post-operative pain or cancer pain.

[0124] 2.35 A method of treating or lessening the severity of acute, chronic, neuropathic or inflammatory pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpetic neuralgia, general neuralgia, visceral pain, osteoarthritis pain, post-herpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, post-operative pain or cancer pain comprising the administration of a therapeutically effective amount of a compound according to any one of embodiments 1.1-1.52.

[0125] 2.36 A compound according to any one of embodiments 1.1-1.52 for the treatment of peripheral disorders, such as lowering intraocular pressure in glaucoma, and for the treatment of dry eye and dry mouth, including Sjogren's syndrome.

[0126] 2.37 A method for the treatment of peripheral disorders, such as lowering intraocular pressure in glaucoma, and for the treatment of dry eye and dry mouth, including Sjogren's syndrome, comprising administration of a therapeutically effective dose of a compound according to any one of embodiments 1.1-1.52.

[0127] 2.38 Use of a compound according to any one of embodiments 1.1-1.52 for the manufacture of a medicament for treating or reducing the severity of acute, chronic, neuropathic or inflammatory pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpetic neuralgia, general neuralgia, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, post-operative pain or cancer pain, or for the treatment of peripheral disorders, such as reducing intraocular pressure in glaucoma, and for the treatment of dry eye and dry mouth, including Sjogren's syndrome.

[0128] 2.39 Use of a compound according to any one of embodiments 1.1 to 1.52 for the treatment of skin lesions, for example due to pemphigus vulgaris, dermatitis herpetiformis, pemphigoid and other blistering skin conditions.

[0129] 2.40 Use of a compound according to any one of embodiments 1.1 to 1.52 for the treatment, prevention, amelioration or reversal of conditions associated with altered gastrointestinal function and motility, such as functional dyspepsia, irritable bowel syndrome, gastroesophageal acid reflux (GER) and esophageal motility disorders, symptoms of gastroparesis and chronic diarrhea.

[0130] 2.41 Use of a compound according to any one of embodiments 1.1 to 1.52 for the treatment of olfactory dysfunction, such as Bosma-Henkin-Christiansen syndrome, chemical poisoning (e.g. selenium and silver), hypopituitarism, Kallmann syndrome, skull fractures, tumor treatment and hypothyroidism.

[0131] 2.42 Use of a compound according to any one of embodiments 1.1 to 1.52 for the treatment of addiction.

[0132] 2.43 Use of a compound according to any one of embodiments 1.1 to 1.52 for the treatment of movement disorders, such as Parkinson's disease, ADHD, Huntington's disease, Tourette's syndrome and other syndromes associated with dopaminergic dysfunction as a potential pathogenic factor driven disease.

[0133] 2.44 Use of a compound according to any one of embodiments 1.1 to 1.52 for the treatment of behavioral and psychiatric symptoms of dementia (BPSD; including agitation, verbal aggression, physical aggression, depression, anxiety, abnormal motor behavior, elevated mood, irritability, apathy, disinhibition, impulsivity, delusions, hallucinations, sleep changes, and appetite changes). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0134] Process for the preparation of compounds of formula (1) Compounds of formula (1) may be prepared in accordance with synthetic methods well known to those skilled in the art and those described herein.

[0135] Thus, in another embodiment (embodiment 3.1), the present invention provides a process for the preparation of a compound as defined in any one of embodiments 1.1 to 1.52, comprising: (A) under reductive amination conditions, a compound of formula (10):

[0136] [ka] and, Compound of formula (11):

[0137] [ka] Reaction with (R 1 , R 4 , X 1 and X 2 is as defined in any one of embodiments 1.1 to 1.52); or (B) A compound of formula (12):

[0138] [ka] and the formula Cl-C(=O)-O-CH2-R 4 Compound (R 1 , R 4, X 1 and X 2 is as defined in any one of embodiments 1.1 to 1.52); or (C) Compound of formula (1) (R 1 is CH2CONR 5 R 6 (including Compound of formula (13):

[0139] [ka] and the formula R 5 R 6 NH amine (R represents a suitable group such as methyl- or ethyl-, R 4 , R 5 , R 6 , X 1 and X 2 is as defined in any one of embodiments 1.1 to 1.52); or (D) Compound of formula (1) (R 1 is CH2CONR 5 R 6 (including Compound of formula (14):

[0140] [ka] and the formula R 5 R 6 NH amine (wherein R 4 , R 5 , R 6 , X 1 and X 2 is as defined in any one of embodiments 1.1 to 1.52); or (E) A compound of formula (1) (R 1 is OCONR 5 R 6 (including Compound of formula (15):

[0141] [ka] and the formula R 5 R 6 NH amine (wherein R 4 , R 5 , R 6 , X 1 and X 2 is as defined in any one of embodiments 1.1 to 1.52); and, in some cases: (F) Conversion of one compound of formula (1) to another compound of formula (1).

[0142] In variant (A), amine (10) is reacted with ketone (11) under reductive amination conditions. The reductive amination reaction is typically carried out using sodium triacetoxyborohydride (STAB) in a solvent such as dichloromethane (DCM), dichloroethane (DCE), N,N-dimethylformamide (DMF) or methanol (MeOH) containing an acid such as acetic acid (AcOH) or trifluoroacetic acid (TFA), or sodium cyanoborohydride (NaCNBH) in combination with zinc chloride (ZnCl2) in a solvent such as MeOH, or titanium tetraisopropoxide (Ti(O i The reaction is carried out using a borohydride reducing agent such as STAB in a solvent such as DCM or DCE containing an acid such as AcOH or TFA in combination with Pr)4) at ambient to mild heating (e.g., at a temperature of about 20° C. to about 70° C.) Optionally, amine (10) may be present in the reaction as an acid salt such as hydrogen chloride (HCl), hydrogen bromide (HBr) or a TFA salt, optionally in the presence of a tertiary base such as triethylamine (TEA) or N,N-diisopropylamine (DIPEA).

[0143] Amines of formula (10) may be commercially available or, alternatively, may be prepared by simple methods well known to those skilled in the art. For example, compounds of formula (1) (R 1 is CH2CONR 5 R 6 (R 5 and R 6is as defined in any one of embodiments 1.1 to 1.52), an amine of formula (10) can be prepared by the reaction sequence shown in Scheme 1 below.

[0144] [ka] Thus, a protected amino ester (16), in which R represents a suitable group such as methyl- or ethyl-, and the protecting group PG represents a suitable protecting group such as tert-butyloxycarbonyl (BOC), can be reacted with a compound of formula R under suitable conditions to effect the formation of a protected amino amide (17). 5 R 6 NH amine (R 5 and R 6 is as defined in any one of embodiments 1.1-1.52). Typically such conditions are reaction in a solvent such as toluene, optionally in the presence of a tertiary base such as TEA or DIPEA, in combination with a reagent such as trimethylaluminum (Me3Al) at a temperature between about 0° C. and about 110° C. The protected amino ester (16) and the amine R are reacted with a suitable solvent, such as reaction in the presence of isopropylmagnesium chloride (iPrMgCl), or by direct heating, optionally in the presence of a suitable solvent. 5 R 6 Those skilled in the art will know that there are other suitable conditions for effecting the formation of the protected aminoamide (17) from NH. Once the protected aminoamide (17) is formed, the protecting group PG can be removed using suitable conditions to form the amine (18). For example, when the protecting group PG is BOC, suitable conditions for effecting its removal can be reaction with an acid such as HCl in a solvent such as 1,4-dioxane or diethyl ether (EtO), or TFA in a solvent such as DCM.

[0145] Alternatively, the protected aminoamide (17) can be prepared by the reaction sequence shown in Scheme 2 below.

[0146] [ka] Thus, the protected amino ester (16) (where R represents a suitable group such as methyl- or ethyl-, and the protecting group PG represents a suitable protecting group such as BOC) is reacted under conditions suitable to effect hydrolysis of the ester to form the protected amino acid (19). Typically, such conditions are reaction with a reagent such as lithium hydroxide (LiOH), sodium hydroxide (NaOH), or potassium hydroxide (KOH) in a solvent such as tetrahydrofuran (THF), MeOH, ethanol (EtOH), water (HO), or a combination of two or more of the aforementioned solvents, at a temperature between about 0° C. and about 100° C. Once formed, the protected amino acid (19) can be reacted with a compound of formula R under conditions suitable to effect formation of the protected amino amide (17). 5 R 6 NH amine (R 5 and R 6 is as defined in any one of embodiments 1.1 to 1.52). 5 R 6 A number of suitable conditions can be used to effect the formation of the protected aminoamide (18) from NH, for example, diisopropylcarbodiimide (DIC), ethyl-(N',N'-dimethylamino)propylcarbodiimide hydrochloride (EDC), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (P) in a solvent such as DCM, THF or DMF, optionally in the presence of 1-hydroxybenzotriazole (HOBt), optionally in the presence of a tertiary base such as TEA or DIPEA, at a temperature between about 0°C and about 100°C. It will be well known to those skilled in the art that reactions with amide coupling reagents such as yBOP), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU) or 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (T3P) exist in the art.

[0147] Alternatively, the protected aminoamide (17) can be prepared by the reaction sequence shown in Scheme 3 below.

[0148] [ka] Thus, protected amino acid (19) (where the protecting group PG represents a suitable protecting group such as BOC) can be reacted under suitable conditions to effect the formation of protected intermediate (20) (where LG represents a suitable leaving group such as chlorine (Cl), 1-imidazole or RO(C=O)O (where R represents a group such as ethyl- or isobutyl-). Typically such conditions are reaction with a reagent such as oxalyl chloride or thionyl chloride (LG=Cl), 1,1'-carbonyldiimidazole (CDI) (LG=1-imidazole), or ethyl or isobutyl chloroformate (LG=RO(C=O)O) in a suitable solvent such as DCM, THF or DMF, optionally in the presence of a catalyst such as DMF, and optionally in the presence of a tertiary base such as TEA or DIPEA. Once formed, protected intermediate (20) can be reacted under suitable conditions to effect the formation of protected aminoamide (17) of formula R 5 R 6 NH amine (R 5 and R 6 is as defined in any one of embodiments 1.1 to 1.52). Typically, such conditions are in a solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA, at a temperature between about 0° C. and about 100° C.

[0149] Alternatively, the compound of formula (1) (R 1 is OCONR 5 R 6 (R 5 and R 6 is as defined in any one of embodiments 1.1 to 1.52), an amine of formula (10) can be prepared by the reaction sequence shown in Scheme 4 below.

[0150] [ka] Thus, protected amino alcohol (21) (where the protecting group PG represents a suitable protecting group such as BOC) can be reacted under suitable conditions to effect the formation of protected intermediate (22) (where LG represents a suitable leaving group such as Cl, 1-imidazole or 4-nitrophenol). Typically such conditions are reaction with a reagent such as phosphogen or triphosphogen (LG=Cl), CDI (LG=1-imidazole) or 4-nitrophenyl-chloroformate (LG=4-nitrophenol) in a suitable solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA. Once formed, protected intermediate (22) can be reacted under suitable conditions to effect the formation of a protected amino carbamate (23) of formula R 5 R 6 NH amine (R 5 and R 6 is as defined in any one of embodiments 1.1 to 1.52). Typically, such conditions are in a solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA, at a temperature between about 0° C. and about 100° C.

[0151] Ketones of formula (11) can be prepared by the reaction sequence shown in Scheme 5 below.

[0152] [ka] Thus, the protected aminoketone (25) (X 1 and X 2is as defined in any one of embodiments 1.1 to 1.52, and PG represents a suitable protecting group, such as BOC or CBZ), can be deprotected to give aminoketone (26). For example, when protecting group PG is BOC, suitable conditions for effecting its removal can be reaction with an acid, such as HCl in a solvent, such as 1,4-dioxane or Et2O, or TFA in a solvent, such as DCM. Alternatively, when protecting group PG is CBZ, suitable conditions for effecting its removal can be reaction with H2 in the presence of a palladium on carbon (Pd / C) catalyst in a solvent, such as EtOH, at a temperature of about 20° C. to about 80° C. Once formed, aminoketone (26) can be converted to chloroformate (27) (R 4 is as defined in any one of embodiments 1.1 to 1.52). Typically, such conditions are in a solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA, at a temperature between about 0° C. and about 50° C.

[0153] In variant (B), the compound of formula (12) is typically reacted with a compound of formula Cl-C(=O)-O-CH2-R in a solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA, at a temperature between about 0°C and about 50°C. 4 Compound (R 4 is as defined in any one of embodiments 1.1 to 1.52).

[0154] Compounds of formula (12) may be prepared using the reaction sequence depicted in Scheme 6 below.

[0155] [ka] Therefore, the compound of formula (10) (R 1 is as defined in any one of embodiments 1.1 to 1.52), under reductive amination conditions, to a compound of formula (25) (X 1 and X2 is as defined in any one of embodiments 1.1-1.52, and PG represents a suitable protecting group, such as BOC or CBZ, to form a compound of formula (28). The reductive amination reaction is typically carried out using a borohydride reducing agent such as STAB in a solvent such as DCM, DCE, DMF or MeOH containing an acid such as AcOH or TFA, or NaCNBH3 in combination with ZnCl2 in a solvent such as MeOH, or STAB in a solvent such as DCM or DCE containing an acid such as AcOH or TFA, in combination with Ti(OiPr)4, at ambient temperature to mild heating (e.g., at a temperature of about 20° C. to about 70° C.). Optionally, compound (10) may be present in the reaction as an acid salt, such as HCl, HBr or TFA salt, optionally in the presence of a tertiary base such as TEA or DIPEA. Once formed, the protecting group PG can be removed from the compound of formula (28) to form a compound of formula (12). For example, when the protecting group PG is BOC, suitable conditions for its removal can be reaction with an acid such as HCl in a solvent such as 1,4-dioxane or EtO, or TFA in a solvent such as DCM. Alternatively, when the protecting group PG is CBZ, suitable conditions for its removal can be reaction with H in the presence of a Pd / C catalyst in a solvent such as EtOH at a temperature of about 20° C. to about 80° C.

[0156] In variant (C), a compound of formula (13) is typically converted to a compound of formula R by combination with a reagent such as MeAl, optionally in the presence of a tertiary base such as TEA or DIPEA, in a solvent such as toluene, at a temperature between about 0° C. and about 110° C. 5 R 6 NH amine (R 5 and R 6 is as defined in any one of embodiments 1.1 to 1.52) in a suitable solvent. i Those skilled in the art will be aware that there are other suitable conditions to effect the same transformation, such as reaction in the presence of PrMgCl or direct heating, optionally in the presence of a suitable solvent.

[0157] Compounds of formula (13) can be prepared by the reactions depicted in Scheme 7 below.

[0158] [ka] Thus, an amine of formula (29) (R represents a suitable group such as methyl- or ethyl-) can be converted under reductive amination conditions to a compound of formula (11) (R 4 , X 1 and X 2 is as defined in any one of embodiments 1.1 to 1.52) to form a compound of formula (13). The reductive amination reaction is typically carried out using STAB in a solvent such as DCM, DCE, DMF or MeOH containing an acid such as AcOH or TFA, or NaCNBH3 in combination with ZnCl2 in a solvent such as MeOH, or Ti(O i The reaction is carried out using a borohydride reducing agent such as STAB in a solvent such as DCM or DCE containing an acid such as AcOH or TFA in combination with Pr)4 at ambient temperature to mild heating (e.g., at a temperature of about 20° C. to about 70° C.). Optionally, amine (29) may be present in the reaction as an acid salt, such as an HCl, HBr or TFA salt, optionally in the presence of a tertiary base such as TEA or DIPEA.

[0159] In variant (D), compounds of formula (14) can be converted to compounds of formula R using suitable amide coupling conditions. 5 R 6 NH amine (R 5 and R 6 is as defined in any one of embodiments 1.1 to 1.52). 5 R 6It will be well known to those skilled in the art that there are numerous suitable conditions for the formation of amides from amines of NH, for example using reagents such as DIC, EDC, PyBOP, HATU, COMU or T3P in solvents such as DCM, THF or DMF, optionally in the presence of HOBt, and optionally in the presence of a tertiary base such as TEA or DIPEA, at temperatures between about 0° C. and about 100° C. Alternatively, compounds of formula (14) can be prepared by the reaction of a carboxylic acid of formula R using the reaction sequence shown in Scheme 8 below. 5 R 6 It can be reacted with amines of NH.

[0160] [ka] Therefore, the compound of formula (14) (R 4 , X 1 and X 2 is as defined in any one of embodiments 1.1 to 1.52) can be reacted under suitable conditions to effect the formation of intermediate (30) (LG represents a suitable leaving group such as Cl, 1-imidazole or RO(C=O)O (R represents a group such as ethyl- or isobutyl-). Typically such conditions are reaction with a reagent such as oxalyl chloride or thionyl chloride (LG=Cl), CDI (LG=1-imidazole), or ethyl or isobutyl chloroformate (LG=RO(C=O)O) in a suitable solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA, and optionally in the presence of a catalyst such as DMF. Once formed, intermediate (30) can be reacted under suitable conditions to effect the formation of a compound of formula (31) with a compound of formula R 5 R 6 NH amine (R 5 and R 6 is as defined in any one of embodiments 1.1 to 1.52). Typically, such conditions are in a solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA, at a temperature between about 0° C. and about 100° C.

[0161] Compounds of formula (14) can be prepared by the reactions depicted in Scheme 9 below.

[0162] [ka] Thus, compounds of formula (13), where R represents a suitable group such as methyl- or ethyl-, 4 , X 1 and X 2 (wherein is as defined in any one of embodiments 1.1-1.52) can be reacted under conditions suitable to effect hydrolysis of the ester to form a compound of formula (14), for example, with a reagent such as LiOH, NaOH, or KOH in a solvent such as THF, MeOH, EtOH, HO, or a combination of two or more of the aforementioned solvents, at a temperature between about 0° C. and about 100° C.

[0163] In process variant (E), a compound of formula (15) is reacted with a compound of formula R under conditions suitable for effecting the formation of a carbamate. 5 R 6 NH amine (R 5 and R 6 is as defined in any one of embodiments 1.1 to 1.52). Typically, such conditions can be as illustrated in Scheme 10 below.

[0164] [ka] Therefore, the compound of formula (15) (R 4 , X 1 and X 2is as defined in any one of embodiments 1.1 to 1.52) is first reacted under suitable conditions to effect the formation of intermediate (32) (LG represents a suitable leaving group such as Cl, 1-imidazole or 4-nitrophenol). Typically such conditions are reaction with a reagent such as phosphogen or triphosphogen (LG=Cl), CDI (LG=1-imidazole) or 4-nitrophenyl-chloroformate (LG=4-nitrophenol) in a suitable solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA. Once formed, intermediate (32) is reacted with a compound of formula R under suitable conditions to effect the formation of dicarbamate (33). 5 R 6 NH amine (R 5 and R 6 is as defined in any one of embodiments 1.1 to 1.52). Typically, such conditions are in a solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA, at a temperature between about 0° C. and about 100° C.

[0165] Compounds of formula (15) can be prepared using the reaction sequence shown in Scheme 11 below.

[0166] [ka] Thus, azetidin-3-ol (34) can be converted under reductive amination conditions to ketones of formula (11) (R 4 , X 1 and X 2 is as defined in any one of embodiments 1.1-1.52) to form a compound of formula (15). The reductive amination reaction is typically carried out using STAB in a solvent such as DCM, DCE, DMF or MeOH containing an acid such as AcOH or TFA, or NaCNBH3 in combination with ZnCl2 in a solvent such as MeOH, or Ti(O iThe reaction is carried out using a borohydride reducing agent such as STAB in a solvent such as DCM or DCE containing an acid such as AcOH or TFA in combination with azetidin-3-ol (34) at ambient to mild heating (e.g., at a temperature of about 20° C. to about 70° C.). Optionally, azetidin-3-ol (34) may be present in the reaction as an acid salt such as HCl, HBr or TFA salt, optionally in the presence of a tertiary base such as TEA or DIPEA. Alternatively, azetidin-3-ol (34) may be converted under reductive amination conditions to a ketone (X 1 and X 2 is as defined in any one of embodiments 1.1-1.52, and PG represents a suitable protecting group such as BOC or CBZ) to form a protected amino alcohol of formula (35). The reductive amination reaction can be generally carried out as described above. Once formed, the protecting group PG can be removed from the protected amino alcohol of formula (35) to form an amino alcohol of formula (36). For example, when the protecting group PG is BOC, suitable conditions for effecting its removal can be reaction with an acid such as HCl in a solvent such as 1,4-dioxane or Et2O, or TFA in a solvent such as DCM. Alternatively, when the protecting group PG is CBZ, suitable conditions for effecting its removal can be reaction with H2 in the presence of a Pd / C catalyst in a solvent such as EtOH at a temperature of about 20° C. to about 80° C. Once formed, the amino alcohol of formula (36) can be reacted with a chloroformate (27) (R 4 is as defined in any one of embodiments 1.1 to 1.52). Typically, such conditions are in a solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA, at a temperature between about 0° C. and about 50° C.

[0167] In the transformation method (F), one of the compounds of formula (1) can be converted into another compound of formula (1) by methods well known to those skilled in the art. Examples of synthetic procedures for converting one functional group into another are described in standard textbooks such as March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th Edition, Michael B. Smith, John Wiley, 2013 (ISBN: 978-0-470-46259-1), Organic Syntheses, online edition, www.orgsyn.org, (ISSN 2333-3553) and Fiesers' Reagents for Organic Synthesis, volumes 1-17, John Wiley (edited by Mary Fieser) (ISBN: 0-471-58283-2).

[0168] In many of the above reactions, it may be necessary to protect one or more groups to prevent reaction from occurring at undesired locations on the molecule. Examples of protecting groups, as well as methods for protecting and deprotecting functional groups, can be found in Greene's Protective Groups in Organic Synthesis, 5th Edition, Ed. Peter GMWuts, John Wiley, 2014 (ISBN: 9781118057483).

[0169] The compounds made by the methods described above can be isolated and purified by any of a variety of methods well known to those of skill in the art, examples of such methods include recrystallization and chromatographic techniques such as column chromatography (e.g., flash chromatography), HPLC and SFC. Pharmaceutical preparations While it is possible for the active compound to be administered alone, it is preferable to supply it as a pharmaceutical composition (eg, formulation).

[0170] Thus, in another embodiment of the present invention (embodiment 4.1), there is provided a pharmaceutical composition comprising at least one compound of formula (1) as defined in any one of embodiments 1.1 to 1.52, together with at least one pharma- ceutically acceptable excipient.

[0171] In one embodiment (embodiment 4.2), the composition is a tablet composition.

[0172] In another embodiment (embodiment 4.3), the composition is a capsule composition.

[0173] Pharmaceutically acceptable excipients may be selected from, for example, carriers (e.g., solid, liquid, or semi-solid carriers), adjuvants, diluents (e.g., solid diluents such as fillers or bulking agents; and liquid diluents such as solvents and co-solvents), granulating agents, binders, flow aids, coating agents, release-controlling agents (e.g., release-suppressing or delaying polymers or waxes), binding agents, disintegrants, buffering agents, lubricants, preservatives, antifungal and antibacterial agents, antioxidants, buffering agents, tonicity adjusting agents, thickening agents, flavoring agents, sweetening agents, pigments, plasticizers, taste-masking agents, stabilizers, or any other excipients conventionally used in pharmaceutical compositions.

[0174] As used herein, the term "pharmacologically acceptable" means a compound, substance, composition, and / or dosage form that is suitable for use in contact with the tissues of a subject (e.g., a human subject) without undue toxicity, irritation, allergic response, or other problem or complication, within the scope of sound medical judgment, commensurate with a reasonable benefit / risk ratio. Each excipient must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.

[0175] Pharmaceutical compositions containing compounds of formula (1) can be formulated according to known techniques, see, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.

[0176] The pharmaceutical compositions can be in any form suitable for oral, parenteral, topical, intranasal, intrabronchial, sublingual, ocular, otic, rectal, vaginal or transdermal administration.

[0177] Pharmaceutical dosage forms suitable for oral administration include tablets (coated or uncoated), capsules (hard or soft shell), caplets, pills, lozenges, syrups, solutions, powders, granules, elixirs and suspensions, sublingual tablets, wafers, or patches such as buccal patches.

[0178] The tablet composition may contain a unit dose of the active compound together with an inert diluent or carrier, such as a sugar or sugar alcohol, e.g., lactose, sucrose, sorbitol or mannitol; and / or a non-sugar derived diluent, such as sodium carbonate, calcium phosphate, calcium carbonate, or a cellulose or its derivative, such as microcrystalline cellulose (MCC), methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, and starch, such as corn starch. The tablet may also contain such standard ingredients as binders and granulating agents, such as polyvinylpyrrolidone, disintegrants (e.g., swellable cross-linked polymers, such as cross-linked carboxymethylcellulose), lubricants (e.g., stearates), preservatives (e.g., parabens), antioxidants (e.g., BHT), buffers (e.g., phosphate or citrate buffers), and effervescent agents, such as citrate / bicarbonate mixtures. Such excipients are well known and need not be discussed in detail here.

[0179] Tablets can be designed to release drug upon contact with gastric fluids (immediate release tablets) or in a controlled manner over an extended period of time or upon contact with specific areas of the GI tract (controlled release tablets).

[0180] The pharmaceutical composition usually comprises about 1% (w / w) to about 95%, preferably % (w / w) of active ingredient, and 99% (w / w) to 5% (w / w) of pharma- ceutically acceptable excipients (e.g., as defined above), or a combination of such excipients. Preferably, the composition comprises about 20% (w / w) to about 90% of active ingredient, and 80% (w / w) to 10% of pharmaceutical excipients, or a combination of excipients. The pharmaceutical composition comprises about 1% to about 95%, preferably about 20% to about 90% of active ingredient. The pharmaceutical composition according to the invention may be in unit dose form, for example, as ampoules, vials, suppositories, pre-filled syringes, dragees, powders, tablets or capsules.

[0181] Tablets and capsules may contain, for example, 0-20% disintegrant, 0-5% lubricant, 0-5% flow aid and / or 0-99% (w / w) filler and / or extender (depending on drug dose). Tablets and capsules may contain 0-10% (w / w) polymer binder, 0-5% (w / w) antioxidant, 0-5% (w / w) pigment. Slow release tablets additionally typically contain 0-99% (w / w) release controlling (e.g. retarding) polymer (dose dependent). Film coatings for tablets or capsules typically contain 0-10% (w / w) polymer, 0-3% (w / w) pigment and / or 0-2% (w / w) plasticizer.

[0182] Parenteral formulations typically contain 0-20% (w / w) buffer, 0-50% (w / w) co-solvent and / or 0-99% (w / w) water for injection (WFI) (depending on dose, if lyophilized). Formulations for intramuscular depots may also contain 0-99% (w / w) oil.

[0183] The pharmaceutical formulations may be supplied to the patient in a "patient pack" containing an entire course of treatment in a single package, usually a blister pack.

[0184] The compounds of formula (1) are generally provided in unit dosage form, and thus typically contain sufficient compound to achieve a desired level of biological activity. For example, a formulation may contain 1 nanogram to 2 grams of active ingredient, such as 1 nanogram to 2 milligrams of active ingredient. Within these ranges, particular subranges of compound are 0.1 milligrams to 2 grams of active ingredient (more typically 10 milligrams to 1 gram, such as 50 milligrams to 500 milligrams), or 1 microgram to 20 milligrams (e.g. 1 microgram to 10 milligrams, such as 0.1 milligram to 2 milligrams of active ingredient).

[0185] For oral compositions, a unit dosage form may contain from 1 milligram to 2 grams, more typically from 10 milligrams to 1 gram, for example, 50 milligrams to 1 gram, for example, 100 milligrams to 1 gram of active compound.

[0186] The active compound is administered to a patient (e.g., a human or animal patient) in need thereof in an amount sufficient to achieve the desired therapeutic effect (effective amount). The exact amount of compound to be administered can be determined by the supervising physician according to standard procedures.

[0187] The invention will now be illustrated, but not limited to, by reference to specific embodiments described in the following examples. EXAMPLES

[0188] Examples 1-1 to 8-1 The compounds of Examples 1-1 to 8-1 shown in Table 1 below were prepared. The NMR and LCMS characteristics of the compounds, as well as the methods used to prepare them, are set forth in Table 3. The starting materials for each of the examples are listed in Table 2.

[0189] [Table 1] General Procedure Where preparative routes are not included, relevant intermediates are commercially available. Commercially available reagents were utilized without further purification. Room temperature (rt) refers to approximately 20-27 °C. 1 H NMR spectra were recorded at 400 MHz on either Bruker or Jeol instruments. Chemical shift values ​​are expressed in parts per million (ppm), i.e. (δ) values. The following abbreviations are used for the multiplicities of NMR signals: s = singlet, br = broad, d = doublet, t = triplet, q = quartet, quint = quintet, td = triplet of doublets, tt = triplet of triplets, qd = quartet of doublets, ddd = doublet of doublet of doublets, ddt = doublet of triplet of doublets, m = multiplet. Coupling constants are listed as J values ​​measured in Hz. NMR and mass spectroscopy results were corrected to account for background peaks. Chromatography refers to column chromatography performed using 60-120 mesh silica gel and carried out under nitrogen pressure (flash chromatography) conditions. TLC for monitoring reactions refers to TLC performed using the indicated mobile phase and silica gel F254 as stationary phase from Merck. Microwave-mediated reactions were performed on a Biotage initiator or a CEM Discover microwave reactor. LCMS analysis LCMS analysis of compounds was performed under electrospray conditions using the equipment and methods shown in the table below.

[0190] The LCMS data in the experimental entries and in Tables 2 and 3 are presented in the following format: (instrument system, method): mass ion, retention time, UV detection wavelength. [Table A]

[0191] [Table B]

[0192] compound purification Final purification of the compounds was performed by preparative reversed-phase HPLC, chiral HPLC or chiral SFC using the equipment and methods detailed below, where data is presented in the following format: purification technique: [phase (column description, column length x internal diameter, particle size), solvent flow rate, gradient - shown as % of mobile phase B in mobile phase A (elapsed time), mobile phase (A), mobile phase (B)]. Preparative HPLC purification: Shimadzu LC-20AP and UV detector Chiral HPLC purification: Shimadzu LC-20AP binary system with SPD-20A UV detector Chiral SFC purification: Waters SFC200 Purification method A Preparative HPLC: [Reversed phase (X-BRIDGE C-18, 250 × 19 mm, 5 μm), 5 mL / min, gradient 40–65% (22 min), 65% (8 min), 100% (4 min), then 100–40% (6 min), mobile phase (A): 5 mM ammonium bicarbonate in water, (B) 100% acetonitrile]. Purification method B Preparative HPLC: [Reversed phase (X-BRIDGE C-8, 250 × 19 mm, 5 μm), 16 mL / min, gradient 20-60% (30 min), 100% (3 min), then 100-20% (2 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.05% ammonia in water, (B) 100% acetonitrile] Purification method C Preparative HPLC: [Reversed phase (X-BRIDGE C-8, 250 × 19 mm, 5 μm), 15 mL / min, gradient 30–55% (22 min), 100% (2 min), then 100–30% (3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile] Purification method D Preparative HPLC: [Reversed phase (X-BRIDGE C-18, 250 × 19 mm, 5 μm), 15 mL / min, gradient 35–45% (25 min), 100% (5 min), then 100–35% (1 min), mobile phase (A): 5 mM ammonium bicarbonate in water, (B) 100% acetonitrile] Purification method E Preparative HPLC: [Reversed phase (X SELECT PHENYL HEXYL, 250 x 19 mm, 5 μm), 9 mL / min, gradient 15-20% (10 min), 20-25% (70 min), 100% (4 min), then 100-15% (6 min), mobile phase (A): 5 mM ammonium bicarbonate in water, (B) 100% acetonitrile] Purification method F Preparative HPLC: [Reversed phase (X-BRIDGE C-8, 250 × 19 mm, 5 μm), 15 mL / min, gradient 28% (24 min), 100% (3 min), then 100–28% (4 min), mobile phase (A): 5 mM ammonium bicarbonate in water, (B) 100% acetonitrile] Purification method G Preparative HPLC: [Reversed phase (X-BRIDGE C-18, 250 × 19 mm, 5 μm), 17 mL / min, gradient 20% (75 min), 100% (5 min), then 100–20% (5 min), mobile phase (A): 5 mM ammonium bicarbonate in water, (B) 100% acetonitrile] Purification method H Preparative HPLC: [Reversed phase (X SELECT PHENYL HEXYL, 250 × 19 mm, 5 μm), 15 mL / min, gradient 0-30% (25 min), 100% (2 min), then 100-0% (3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile] Purification method I Preparative HPLC: [Reversed phase (X-BRIDGE C-8, 250 × 19 mm, 5 μm), 15 mL / min, gradient 23–27% (20 min), 27% (25 min), 27–100% (15 min), 100% (1 min), then 100–23% (2 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile] Purification method J Preparative HPLC: [Reversed phase (X-BRIDGE C-8, 250 × 19 mm, 5 μm), 17 mL / min, gradient 20–55% (16 min), 100% (3 min), then 100–20% (3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.05% ammonia in water, (B) 100% acetonitrile] Purification method K Preparative HPLC: [Reversed phase (X-BRIDGE C-8, 250 × 19 mm, 5 μm), 17 mL / min, gradient 20-30% (40 min), 100% (4 min), then 100-20% (6 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.05% ammonia in water, (B) 100% acetonitrile] Purification method L Preparative HPLC: [Reversed phase (X-BRIDGE C-8, 250 × 19 mm, 5 μm), 17 mL / min, gradient 23–33% (20 min), 33% (15 min), 100% (4 min), then 100–23% (4 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.05% ammonia in water, (B) 100% acetonitrile] Purification method M Preparative HPLC: [Reversed phase (X-BRIDGE C-18, 250 × 19 mm, 5 μm), 17 mL / min, gradient 28-34% (25 min), 100% (2 min), then 100-28% (3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.05% ammonia in water, (B) 100% acetonitrile] Purification method N Preparative HPLC: [Reversed phase (X-BRIDGE C-18, 250 × 19 mm, 5 μm), 16 mL / min, gradient 10–26% (20 min), 26–29% (33 min), 29% (23 min), 100% (3 min), then 100–10% (6 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile] Purification method O Preparative HPLC: [reversed phase (X-BRIDGE C-8, 250 × 19 mm, 5 μm), 15 mL / min, gradient 10–50% (28 min), 50% (4 min), 100% (2 min), then 100–10% (3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B): acetonitrile:methanol (50:50)] Purification method P Preparative HPLC: [Reversed phase (X-BRIDGE C-18, 250 × 19 mm, 5 μm), 15 mL / min, gradient 15–30% (30 min), 30% (5 min), 100% (2 min), then 100–15% (3 min), mobile phase (A): 5 mM ammonium acetate in water, (B) 100% acetonitrile] Purification method Q SFC: [(CHIRALCEL OX-H, 250 × 21 mm, 5 μm), 70 mL / min, isocratic solvent (A:B) (80:20) (10 min), mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in isopropanol] Purification method R Preparative HPLC: [Reversed phase (X-BRIDGE C-8, 250 × 19 mm, 5 μm), 17 mL / min, gradient 0% (3 min), 0–50% (30 min), 100% (2 min), then 100–0% (2 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile] Purification method S SFC: [(CHIRALCEL OX-H, 250 × 21 mm, 5 μm), 70 mL / min, isocratic solvent (A:B) (85:15) (10 min), mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in methanol] Purification method T Preparative HPLC: [Reversed phase (X-BRIDGE C-8, 250 × 19 mm, 5 μm), 15 mL / min, gradient 10–40% (18 min), 40% (5 min), 100% (2 min), then 100–10% (3 min), mobile phase (A): 10 mM ammonium acetate in water, (B) 100% acetonitrile] Purification method U Preparative HPLC: [Reversed phase (X SELECT PHENYL HEXYL, 250 × 19 mm, 5 μm), 15 mL / min, gradient 0-60% (25 min), 100% (2 min), then 100-0% (3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile] Purification method V Chiral HPLC: [normal phase (CHIRALCEL OX-H, 250 × 21 mm, 5 μm), 18 mL / min, isotropic solvent (A:B) (60:40) (25 min), mobile phase (A): 0.1% diethylamine in hexane, (B): 0.1% diethylamine in isopropanol] Purification method W Preparative HPLC: [Reversed phase (X-BRIDGE C-8, 250 × 19 mm, 5 μm), 16 mL / min, gradient 20-30% (18 min), 30% (4 min), 100% (2 min), then 100-20% (3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile] Purification method X SFC: [(CHIRALCEL OX-H, 250 × 21 mm, 5 μm), 70 mL per min, isocratic solvent (A:B) (85:15) (14 min), mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in isopropanol] Purification method Y Preparative HPLC: [reverse phase (PHENOMENEX LUNA C-18, 250 × 21.2 mm, 5 μm), 16 mL / min, gradient 15–45% (25 min), 100% (2 min), then 100–15% (3 min), mobile phase (A): 10 mM ammonium acetate in water, (B) 100% acetonitrile] Purification method Z Preparative HPLC: [Reversed phase (X SELECT PHENYL HEXYL, 250 × 19 mm, 5 μm), 16 mL / min, gradient 30-55% (30 min), 55% (3 min), 100% (2 min), then 100-30% (2 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile] Purification method AA Preparative HPLC: [Reversed phase (X-BRIDGE C-18, 250 × 19 mm, 5 μm), 15 mL / min, gradient 15–58% (23 min), 100% (2 min), then 100–15% (2 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile] Purification method AB Preparative HPLC: [Reversed phase (X-BRIDGE C-8, 250 × 19 mm, 5 μm), 18 mL / min, gradient 25–56% (20 min), 100% (2 min), then 100–25% (3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.05% ammonia in water, (B) 100% acetonitrile] Purification method AC Preparative HPLC: [Reversed phase (X-BRIDGE C-8, 250 × 19 mm, 5 μm), 16 mL / min, gradient 10–45% (16 min), 45% (6 min), 100% (2 min), then 100–10% (4 min), mobile phase (A): 5 mM ammonium bicarbonate in water, (B) 100% acetonitrile]. Purification method AD Preparative HPLC: [Reversed phase (X-BRIDGE C-18, 250 × 19 mm, 5 μm), 16 mL / min, gradient 30–42% (18 min), 42% (10 min), 100% (2 min), then 100–30% (3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.05% ammonia in water, (B) 100% acetonitrile] Purification method AE Preparative HPLC: [Reversed phase (X SELECT PHENYL HEXYL, 250 × 19 mm, 5 μm), 15 mL / min, gradient 5–25% (20 min), 100% (2 min), then 100–5% (3 min), mobile phase (A): 0.1% formic acid in water, (B) 100% acetonitrile] Refining method AF Preparative HPLC: [Reversed phase (X-BRIDGE C-18, 250 × 19 mm, 5 μm), 13 mL / min, gradient 10-50% (22 min), 100% (3 min), then 100-10% (5 min), mobile phase (A): 10 mM ammonium acetate in water, (B) 100% acetonitrile] Purification method AG Preparative HPLC: [Reversed phase (X-BRIDGE C-8, 250 × 19 mm, 5 μm), 16 mL / min, gradient 32% (50 min), 100% (3 min), then 100–32% (3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.05% ammonia in water, (B) 100% acetonitrile] Purification method AH Preparative HPLC: [reversed phase (SUNFIRE C-18, 250 × 19 mm, 5 μm), 13 mL / min, gradient 0–17% (25 min), 17% (7 min), 100% (2 min), then 100–0% (3 min), mobile phase (A): 0.1% formic acid in water, (B) 100% acetonitrile]. Abbreviation DCM = dichloromethane ES(I) = electrospray ionization EtOAc = ethyl acetate h = time H2O = Water HCl = Hydrogen chloride, hydrochloric acid HPLC = High Performance Liquid Chromatography IPA = Propan-2-ol Lc = liquid chromatography MeOH = methanol min(s) = minutes MS = mass spectrometry nm = nanometers NMR = nuclear magnetic resonance SFC = Supercritical Fluid Chromatography TEA = triethylamine TFA = trifluoroacetic acid TLC = thin layer chromatography The prefixes n-, s-, i-, t- and tert- have their usual meanings: normal, secondary, iso and tertiary. Synthesis of intermediates: Route 1 A typical procedure for the preparation of esters, exemplified by the preparation of intermediate 3, ethyl-3-(3-(2-methoxy-2-oxoethyl)azetidin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylate.

[0193] [ka] tert-Butyl 3-(2-methoxy-2-oxoethyl)azetidine-1-carboxylate (Intermediate 1) (150 mg, 0.66 mmol) was dissolved in DCM (5 mL) and cooled to 0° C. To this, TFA (1 mL) was added dropwise and the resulting reaction mixture was stirred at room temperature for 5 h. The solvent was removed in vacuo and the residue was purified by trituration with diethyl ether (3×1 mL) to give methyl 2-(azetidin-3-yl)acetate trifluoroacetate (110 mg, >100%) as a gum. LCMS (System 1, Method C): m / z 130 (M+H) + (ESI+ve), 2.37 min, 202nm.

[0194] Methyl 2-(azetidin-3-yl)acetate trifluoroacetate (200 mg, 1.55 mmol), ethyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (Intermediate 2) (305 mg, 1.55 mmol), TEA (0.7 mL, 4.65 mmol) and ZnCl2 (21 mg, 0.16 mmol) were dissolved in MeOH (10 mL) and the reaction mixture was stirred at 65 °C for 8 h. The reaction was then cooled to 0 °C and then NaBH3CN (293 mg, 4.65 mmol) was added to it in portions. The resulting reaction mixture was stirred at 60 °C for 30 h. The solvent was removed in vacuo and the residue was partitioned between HO (100 mL) and EtOAc (80 mL) and the aqueous layer was further extracted with EtOAc (2 x 80 mL). The combined organic phase was dried (Na2SO4) and removed in vacuo, and the residue was purified by column chromatography (normal phase neutral activated alumina, 50% to 60% EtOAc in hexanes) to give ethyl-3-(3-(2-methoxy-2-oxoethyl)azetidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (Intermediate 3) (140 mg, 29%) as a gum.

[0195] Data for intermediate 3 is in Table 2. Route 2 A typical procedure for the preparation of ketones, exemplified by the preparation of intermediate 8, ethyl 5-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate.

[0196] [ka] A solution of tert-butyl 5-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate (Intermediate 12) (550 mg, 2.44 mmol) and TFA (2.50 mL) in DCM (5 mL) was stirred at room temperature under nitrogen for 3 h. The reaction mixture was concentrated in vacuo and the residue was co-evaporated from diethyl ether (2×5 mL) and toluene (2×10 mL) to give 2-azabicyclo[2.2.2]octan-5-one trifluoroacetate (280 mg, 92%) as a gum. LCMS (System 1, Method C): m / z 126 (M+H) + (ESI+ve), 1.41 min, 202nm.

[0197] A solution of 2-azabicyclo[2.2.2]octan-5-one trifluoroacetate (275 mg, 2.20 mmol) and TEA (0.92 mL, 6.59 mmol) in DCM (10 mL) was stirred under nitrogen at 0 °C for 10 min. To this was then added ethyl carbonochloridate (Intermediate 13) (356 mg, 3.30 mmol) dropwise at 0 °C-10 °C, and the reaction was then warmed to room temperature and stirred for 2 h. The reaction mixture was partitioned between HO (20 mL) and EtOAc (15 mL) and the aqueous layer was further extracted with EtOAc (2 x 15 mL). The combined organic phase was dried (Na2SO4), concentrated in vacuo and the residue was purified by column chromatography (normal phase silica, 0% to 2% MeOH in DCM) to give ethyl-5-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate (Intermediate 8) (308 mg, 71%) as a gum.

[0198] Data for intermediate 8 is in Table 2. Route 3 Typical procedure for the preparation of carbamates, exemplified by the preparation of intermediate 20, azetidin-3-yl diethyl carbamate trifluoroacetate.

[0199] [ka] To a stirred solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (Intermediate 18) (3.0 g, 17.3 mmol) in DCM (90 mL) was added TEA (12.5 mL, 86.7 mmol). The reaction was stirred at room temperature for 15 minutes and then cooled to 0° C. To this was then added 4-nitrophenyl carbonochloridate (Intermediate 19) (12.2 g, 60.7 mmol) in portions and then the reaction was allowed to warm to room temperature and stirred for 4 hours. To this was then added diethylamine (Intermediate 4) (4.4 mL, 60.7 mmol) and the reaction was allowed to stir at room temperature for 16 hours. The reaction mixture was partitioned between H2O (30 mL) and DCM (50 mL). The organic phase was concentrated in vacuo and the residue was purified by column chromatography (neutral alumina, EtOAc in hexanes) to give tert-butyl 3-((diethylcarbamoyl)oxy)azetidine-1-carboxylate (3.6 g, 74%) as a gum. LCMS (System 2, Method D): m / z 273 (M+H) + (ESI+ve), 1.99 min, 202 nm.

[0200] To a stirred solution of tert-butyl 3-((diethylcarbamoyl)oxy)azetidine-1-carboxylate (1.0 g, 3.7 mmol) in DCM (15 mL) at 0° C. was added TFA (5 mL) dropwise. The reaction was allowed to warm to room temperature and stirred for 3 h. The reaction mixture was concentrated in vacuo and co-evaporated from toluene (×3) to give azetidin-3-yl diethylcarbamate trifluoroacetate (Intermediate 20) (500 mg, 80%) as a gum.

[0201] Data for intermediate 20 is in Table 2. Route 4 Typical procedure for the preparation of carbamates, exemplified by the preparation of intermediate 23, azetidin-3-yl 1,4-oxazepane-4-carboxylate hydrochloride.

[0202] [ka] To a stirred solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (Intermediate 18) (400 mg, 2.31 mmol) in DCM (20 mL) was added TEA (1.6 mL, 11.6 mmol). The reaction was stirred at room temperature for 15 minutes and then cooled to 0° C. To this was then added 4-nitrophenyl carbonochloridate (Intermediate 19) (1.6 g, 8.09 mmol) in portions and then the reaction was allowed to warm to room temperature and stirred for 4 hours. To this was then added 1,4-oxazepane (Intermediate 10) (310 mg, 2.31 mmol) and the reaction was allowed to stir at room temperature for 16 hours. The reaction mixture was partitioned between H2O (5 mL) and DCM (20 mL). The organics were dried (Na2SO4) and concentrated in vacuo, and the residue was purified by column chromatography (neutral alumina, EtOAc in hexanes) to afford 1-(tert-butoxycarbonyl)azetidin-3-yl 1,4-oxazepane-4-carboxylate (200 mg, 28%) as a gum. LCMS (System 3, Method E): m / z 301 (M+H) + (ESI+ve), 3.37 min, 202nm.

[0203] To a stirred solution of 1-(tert-butoxycarbonyl)azetidin-3-yl 1,4-oxazepane-4-carboxylate (400 mg 1.33 mmol) in 1,4-dioxane (5 ml) at 0° C. was added dropwise a solution of HCl in 1,4-dioxane (4 M, 5 mL, 20 mmol). The reaction was allowed to warm to room temperature and stirred for 3 h. The reaction mixture was concentrated in vacuo and triturated with diethyl ether and pentane to give azetidin-3-yl 1,4-oxazepane-4-carboxylate hydrochloride (Intermediate 23) (200 mg, 75%) as a gum.

[0204] Data for intermediate 23 are in Table 2. Route 5 A typical procedure for the preparation of alcohols, exemplified by the preparation of intermediate 34, ethyl 5-(3-hydroxyazetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate.

[0205] [ka] To a solution of azetidin-3-ol hydrochloride (Intermediate 33) (500 mg, 4.59 mmol) and TEA (3.18 mL, 22.9 mmol) in MeOH (10 mL) was added ethyl 5-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate (Intermediate 8) followed by a solution of ZnCl2 in diethyl ether (1 M, 0.23 mL, 0.23 mmol). The reaction mixture was stirred at 80 °C for 5 h and then cooled to 0 °C. NaBH3CN (853 mg, 13.7 mmol) was added and the reaction was allowed to warm to room temperature and stirred for 18 h. The reaction mixture was partitioned between H2O (150 mL) and EtOAc (40 mL). The aqueous layer was further extracted with EtOAc (2×40 mL) and the combined organic phases were dried (Na2SO4) and concentrated in vacuo, and the residue was purified by column chromatography (neutral alumina, 0% to 4% MeOH in DCM) to give ethyl-5-(3-hydroxyazetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate (Intermediate 34) (400 mg, 34%) as a liquid.

[0206] Data for intermediate 34 is in Table 2. General synthetic procedure: Route A A typical procedure for the preparation of amides, exemplified by the preparation of Example 1-1, ethyl-3-(3-(2-(diethylamino)-2-oxoethyl)azetidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate.

[0207] [ka] To a solution of diethylamine (Intermediate 4) (99 mg, 1.35 mmol) in toluene (10 mL) was added TEA (0.2 mL, 1.35 mmol). The reaction was then cooled to -10 °C, to which was then added a solution of trimethylaluminum in toluene (2.0 M, 0.7 mL, 1.35 mmol) and the reaction mixture was stirred at -10 °C to 0 °C for 20 min, followed by the addition of ethyl-3-(3-(2-methoxy-2-oxoethyl)azetidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (Intermediate 3) (140 mg, 0.45 mmol) at -10 °C. The resulting reaction mixture was then stirred at 80 °C for 50 h. The solvent was removed in vacuo and the residue was partitioned between HO (10 mL) and DCM (80 mL) and the aqueous layer was further extracted with DCM (2 x 80 mL). The combined organic phases were dried (Na2SO4), concentrated in vacuo, and the residue was purified by purification method A to give ethyl-3-(3-(2-diethylamino)-2-oxoethyl)azetidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate, Example 1-1 Isomer 1 (4 mg, 3%) as a yellow gum and ethyl-3-(3-(2-(diethylamino)-2-oxoethyl)azetidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate, Example 1-1 Isomer 2 (47 mg, 30%) as a gum.

[0208] Data for Example 1-1 Isomer 2 is in Table 3. Route B A typical procedure for the preparation of amines, exemplified by the preparation of Example 4-1, ethyl 6-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-2-azaspiro[3.3]heptane-2-carboxylate.

[0209] [ka] A solution of azetidin-3-yl diethylcarbamate trifluoroacetate (Intermediate 20) (200 mg, 1.16 mmol) and TEA (0.5 mL, 3.49 mmol) in MeOH (2 mL) was stirred at room temperature for 15 min. To this was then added ethyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (Intermediate 21) (160 mg, 0.87 mmol), followed by a solution of ZnCl2 in diethyl ether (1 M, 0.6 mL, 0.060 mmol). The reaction was stirred at 90 °C for 4 h, then cooled to 0 °C, followed by the addition of NaBH3CN (146 mg, 2.32 mmol) in portions. The resulting reaction mixture was stirred at 90 °C for 16 h. The solvent was removed in vacuo, the residue was partitioned between HO (200 mL) and EtOAc (200 mL), and the aqueous layer was further extracted with EtOAc (2×200 mL). The combined organic phases were dried (NaSO) and concentrated in vacuo, and the residue was purified by purification method M to give ethyl 6-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-2-azaspiro[3.3]heptane-2-carboxylate, Example 4-1 (35 mg, 9%) as a colorless gum.

[0210] Data for Example 4-1 is in Table 3. Route C A typical procedure for the preparation of carbamates, exemplified by the preparation of Example 6-1, ethyl 5-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-2-azaspiro[2.2.2]octane-2-carboxylate.

[0211] [ka] To a solution of ethyl 5-(3-hydroxyazetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate (Intermediate 34) (100 mg, 0.39 mmol) in DCM (5 mL) was added TEA (0.1 mL, 1.18 mmol) followed by 4-nitrophenyl carbonochloridate (Intermediate 19) (94 mg, 0.47 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 5 hours. To this was then added diethylamine (Intermediate 4) (0.1 mL, 0.79 mmol) and the reaction was stirred at room temperature for 16 hours. The reaction was partitioned between HO (150 mL) and EtOAc (40 mL). The aqueous layer was further extracted with EtOAc (2×40 mL) and the combined organic phases were dried (NaSO) and concentrated in vacuo, and the residue was purified by purification method B1 to give ethyl-5-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate, Example 6-1 Isomer 1 (28 mg, 20%) as a colorless gum and ethyl-5-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-2-azabicyclo[2.2.1]octane-2-carboxylate, Example 6-1 Isomer 2 (13 mg, 9%) as a colorless gum.

[0212] Data for Example 6-1 Isomer 1 is in Table 3.

[0213] [Table 2-1]

[0214] [Table 2-2]

[0215] [Table 2-3]

[0216] [Table 3-1]

[0217] [Table 3-2]

[0218] [Table 3-3]

[0219] [Table 3-4]

[0220] [Table 3-5]

[0221] [Table 3-6]

[0222] [Table 3-7] biological activity Example A Phospho-ERK1 / 2 assay Functional assays were performed using the Alphascreen Surefire phospho-ERK1 / 2 assay (Crouch & Osmond, Comb. Chem. High Throughput Screen, 2008). ERK1 / 2 phosphorylation is a downstream consequence of both Gq / 11 and Gi / o protein-coupled receptor activation, making it highly suitable for evaluation of M1, M3 (Gq / 11-coupled) and M2, M4 receptors (Gi / o-coupled) rather than using different assay formats for different receptor subtypes. CHO cells stably expressing human muscarinic M1, M2, M3 or M4 receptors were plated (25K / well) in 96-well tissue culture plates in MEM-alpha + 10% dialyzed FBS. Once cells had attached, they were serum-starved overnight. Agonist stimulation was performed by adding 5 μL of agonist to the cells for 5 min (37°C). The medium was removed and 50 μL of lysis buffer was added. After 15 minutes, 4 μL of sample was transferred to a 384-well plate and 7 μL of detection mix was added. The plate was incubated for 2 hours in the dark with gentle agitation and then read on a PHERAstar plate reader. Data obtained for each receptor subtype revealed that pEC 50 and E max The values ​​of were calculated and the results are set forth in Table 4 below.

[0223] For most of the examples, at least two diastereomers are present and, unless otherwise stated, are separated using reversed-phase HPLC, chiral HPLC or chiral SFC techniques. Isomer assignment (isomer 1, isomer 2, etc.) is based on the retention time of the compound using the separation technique performed in the final purification step. By implication, this can be the retention time of reversed-phase HPLC, chiral HPLC or chiral SFC, which will vary from compound to compound.

[0224] Analytical data for the active isomers are reported in Table 3. Data for some of the less active compounds are included in Table 4, highlighting those that are preferred with respect to absolute stereochemistry. NT = not tested

[0225] [Table 4] Equivalent The above examples are presented for the purpose of illustrating the present invention and should not be construed as imposing any limitations on the scope of the present invention. It will be readily apparent that numerous modifications and variations can be made to the specific embodiments of the invention described above and illustrated in the examples without departing from the principles underlying the invention. All such modifications and variations are intended to be encompassed by this application.

Claims

1. Compound of formula (1): 【Chemistry 1】 or a salt thereof, X 1 and X 2 are saturated hydrocarbon groups which together contain a total of 5 to 9 carbon atoms and 0 or 1 oxygen atoms and are represented by the following moieties: 【Chemistry 2】 are saturated hydrocarbon groups linked together to form a bicyclic ring system, which may be substituted by one or more fluorine atoms; R 1 is CONR 5 R 6 ;NR 7 C.O.N.R. 5 R 6 ;OCONR 5 R 6 ;CH 2 C.O.N.R. 5 R 6 ;CH 2 N.R. 7 C.O.N.R. 5 R 6 and CH 2 OCONR 5 R 6 Selected from: R 4 is H or C optionally substituted with 1 to 6 fluorine atoms. 1~6 a non-aromatic hydrocarbon group in which one or two, but not all, carbon atoms of the hydrocarbon group may be replaced by a heteroatom selected from O, N and S and their oxidized forms; R 5 , R 6 and R 7 are the same or different, and each independently represents hydrogen, non-aromatic C 1~6 a hydrocarbon group, optionally substituted by one or more fluorine atoms, or a 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms, or R 5 and R 6 can be joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof).

2. R 1 But, CH 2 C.O.N.R. 5 R 6 or OCONR 5 R 6 2. The compound of claim 1, or a salt thereof, selected from:

3. R 5 But, C 1 ~C 3 alkyl, or R 6 3. The compound of claim 1 or 2, or a salt thereof, which is linked to form a monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof.

4. R 6 But, C 1 ~C 3 alkyl, or R 5 or a salt thereof, which is linked to form a monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof.

5. R 5 and R 6 The compound according to any one of claims 1 to 4, wherein:

6. R 1 but the following: 【Chemistry 3】 6. The compound according to claim 1 , or a salt thereof, selected from:

7. R 4 A compound according to any one of claims 1 to 6, or a salt thereof, wherein is selected from H, methyl, ethyl, ethynyl and 1-propynyl.

8. The following part: 【Chemistry 4】 The bicyclic ring system formed by the following ring system: 【Chemistry 5】 8. The compound according to claim 1 , or a salt thereof, selected from:

9. The compound is selected from the group consisting of: 【Chemistry 6】 9. The compound according to claim 1 , or a salt thereof, selected from:

10. The compound is selected from the group consisting of: Ethyl-3-(3-(2-(diethylamino)-2-oxoethyl)azetidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate; Ethyl-3-(3-(2-(ethyl(isopropyl)amino)-2-oxoethyl)azetidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate; Ethyl-3-(3-(2-oxo-2-(1-azaspiro[3.3]heptan-1-yl)ethyl)azetidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate; Ethyl-3-(3-(2-oxo-2-(piperidin-1-yl)ethyl)azetidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate; Ethyl-5-(3-(2-(diethylamino)-2-oxoethyl)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl-5-(3-(2-(ethyl(isopropyl)amino)-2-oxoethyl)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl-5-(3-(2-oxo-2-(piperidin-1-yl)ethyl)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl-5-(3-(2-(1,4-oxazepan-4-yl)-2-oxoethyl)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl-5-(3-(2-oxo-2-(1-azaspiro[3.3]heptan-1-yl)ethyl)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl-3-(3-(2-(diethylamino)-2-oxoethyl)azetidin-1-yl)-9-azabicyclo[3.3.1]nonane-9-carboxylate; Ethyl-3-(3-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azetidin-1-yl)-9-azabicyclo[3.3.1]nonane-9-carboxylate; Ethyl-3-(3-(2-oxo-2-(piperidin-1-yl)ethyl)azetidin-1-yl)-9-azabicyclo[3.3.1]nonane-9-carboxylate; Ethyl 6-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-2-azaspiro[3.3]heptane-2-carboxylate; Ethyl 2-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate; 1-(6-(ethoxycarbonyl)-6-azaspiro[3.4]octan-2-yl)azetidin-3-yl 1,4-oxazepane-4-carboxylate; Ethyl 6-(3-((ethyl(methyl)carbamoyl)oxy)azetidin-1-yl)-2-azaspiro[3.4]octane-2-carboxylate; Ethyl 6-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-2-azaspiro[3.4]octane-2-carboxylate; Methyl 6-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-2-azaspiro[3.4]octane-2-carboxylate; Ethyl 6-(3-((pyrrolidine-1-carbonyl)oxy)azetidin-1-yl)-2-azaspiro[3.4]octane-2-carboxylate; 1-(2-(ethoxycarbonyl)-2-azaspiro[3.4]octan-6-yl)azetidin-3-ylmorpholine-4-carboxylate; 1-(2-(ethoxycarbonyl)-2-azaspiro[3.4]octan-6-yl)azetidin-3-yl 1,4-oxazepane-4-carboxylate; Ethyl 3-(3-((azepane-1-carbonyl)oxy)azetidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate; 1-(8-(ethoxycarbonyl)-8-azabicyclo[3.2.1]octan-3-yl)azetidin-3-yl 1,4-oxazepane-4-carboxylate; Ethyl 5-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl 5-(3-((pyrrolidine-1-carbonyl)oxy)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl 5-(3-((piperidine-1-carbonyl)oxy)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; Ethyl 5-(3-((azepane-1-carbonyl)oxy)azetidin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate; 1-(2-(ethoxycarbonyl)-2-azabicyclo[2.2.2]octan-5-yl)azetidin-3-yl 1,4-oxazepane-4-carboxylate; Ethyl 3-(3-((diethylcarbamoyl)oxy)azetidin-1-yl)-9-azabicyclo[3.3.1]nonane-9-carboxylate; Ethyl 7-(3-((azepane-1-carbonyl)oxy)azetidin-1-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate; 9. The compound according to claim 1 , or a salt thereof, selected from:

11. A medicament comprising a compound according to any one of claims 1 to 10 or a salt thereof.

12. 11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10 or a salt thereof, and a pharma- ceutically acceptable excipient.

13. Muscarinic M 1 and / or M 4 11. A compound or salt thereof according to any one of claims 1 to 10, which has receptor agonist activity.

14. 13. A pharmaceutical composition according to claim 12 for use in the treatment of a cognitive or psychotic disorder, or for treating or reducing the severity of acute, chronic, neuropathic or inflammatory pain.

15. The pharmaceutical composition of claim 14, wherein the cognitive disorder is Alzheimer's disease.

16. 15. The pharmaceutical composition of claim 14, wherein the cognitive disorder is dementia with Lewy bodies.

Citation Information

Patent Citations

  • Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic m4 receptor agonists

    JP2016507548A